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I 
ABSTRACT 
The heterogeneous group of myopathies can affect the function of the skeletal muscle, as well as 
other organ systems, like the connective tissue, the heart or the lung. Diseases of voluntary muscles 
comprise a huge number of different entities, which may be inherited or acquired. The correct 
diagnosis may be difficult to obtain and the patients’ clinical history, laboratory results and muscle 
biopsies are helpful to distinguish between different entities. Therefore, the classification of muscle 
diseases is constantly changing and getting more detailed. Acquired myopathies are potentially 
treatable, but there are often only unspecific treatment options. In contrast to acquired myopathies, 
there is no causative cure for inherited forms of myopathies. Nevertheless, treatment is warranted to 
increase the quality of life and life expectancy in patients. Therefore, the knowledge of underlying 
pathological and immunological mechanisms in these diseases is highly important. Macrophages, due 
to their multifunctional capacities, are involved in a variety of reactions in the muscle, and it has been 
shown in many studies, that during muscle injury, macrophages are involved in clearing pathogens 
and perform a switch from pro-inflammatory to alternatively activated macrophage phenotypes. 
Moreover, macrophages are important players in autoimmune reactions in myopathies and might 
therefore be an interesting target for specific therapies. 
In the current thesis, three different entities were analyzed. They all share common aspects of the 
immune response, but also feature distinct immunological aspects as well. All entities have an 
inflammatory part in common, which is mainly regulated by influx of immune cells into the muscle and 
adjacent connective tissue. However, the composition of these infiltrates was varying between the 
diseases and the involvement of e.g. lymphocytes or macrophages was variable. In addition, the 
respective cytokine milieu in the muscle tissue was also highly specific in the examined inflammatory 
myopathies and in muscular dystrophies. Thus, the aim of the study was to precisely examine 
interactions between immune cells, and also analyze characteristic pathological phenomena, such as 
hypoxia, inflammation and fibrosis. 
 
Necrotizing myopathies have an immune-mediated background or showed a toxic aetiology. In this 
work I demonstrated that both sub-groups of necrotizing myopathy can clearly be distinguished by 
their morphological characteristics, as well as certain immune aspects, such as presence of 
autoantibodies, B cell invasion and also the underlying cytokine milieu. The immune reaction in 
patients with immune-mediated necrotizing myopathies was defined by a TH1-like, pro-inflammatory 
milieu, with up-regulation of IFN-γ and TNFα. Interestingly, beside muscle fibre necrosis, both groups 
showed a clear inflammatory infiltrate with macrophages invading muscle fibres. Macrophages are the 
predominant cell population and are spread throughout the muscle. In addition, considerable amounts 
of CD4+ and CD8+ T cells are found in the infiltrates of patients with an immune-mediated disease, 
while only few patients showed presence of B cells and plasma cells and expression of the B cell 
chemoattractant CXCL13 was low. Furthermore, a clear expression of MHC class I molecules and 
C5b9 deposition was detected in these cases, while none of these features were found in patients with 
a toxic aetiology, which clearly distinguished both subtypes of necrotizing myopathies.  
  
 
II 
Analyses of the clinical and morphological picture in patients suffering from dermatomyositis showed 
that juvenile patients have very characteristic symptoms, like dysphagia and calcifications of skeletal 
muscles that are not part of the disease in adults. On the other hand, both diseases are considered 
inflammatory vasculopathies, although clear vasculitis with destruction of vessel walls is not apparent. 
A typical perifascicular pattern of atrophy was identified, as well as effects of hypoxia, and both 
features are more pronounced in juvenile patients, as compared to adults. Since these hypoxic 
changes are most salient in the perimysium, as well as in adjacent atrophic muscle fibres, these areas 
were analyzed by qPCR after laser microdissection. Up-regulation of molecules involved in hypoxia 
was found in the perifascicular area, while the centro-fascicular tissue of the same patients showed no 
regulation of hypoxia-associated molecules. In line with these findings, the loss of capillaries in 
dermatomyositis patients was determined. The quantification of capillaries per fibre showed that 
capillary loss was also more prominent in juvenile patients. Taken together, these findings showed 
that hypoxia is involved in development of perifascicular atrophy and that the features described are in 
general more pronounced in juvenile dermatomyositis than in the adult form. 
A number of inherited myopathies are known to also harbor significant inflammatory infiltrates. Among 
these Duchenne muscular dystrophy is the most prominent. Here the development of fibrosis was a 
major feature of skeletal muscle degeneration and directly correlates with early loss of ambulation. 
Patients develop fibrosis, as demonstrate by EvG and collagen VI staining, and expression levels of 
molecules involved in this process, such as TGFβ or the collagen synthetase (P4HA1) were 
significantly elevated in comparison to those of healthy controls. Macrophages are not only strong 
players in inflammatory processes but also tightly control fibrotic processes. In line with this, I showed 
that over time both, inflammation and fibrotic tissue was changing characteristically. Quantification of 
macrophages demonstrated that the highest number of invading cells was seen in patients with an 
age of about four years. However, after loss of ambulation the intensity of inflammatory processes 
decreased. This was monitored by reduced numbers of all inflammatory cells, as well as reduced 
expression of molecules driving inflammation. A computer-based algorithm was used to quantify 
fibrosis, and I demonstrated that the amount of connective tissue increased with the age of patients, 
while at late stage of disease fatty transformation was an additional important issue. Quantifications 
revealed that the ratio between fibres and connective tissue was reduced in Duchenne muscular 
dystrophy in comparison to Becker muscular dystrophy and female carriers of the DMD gene mutation. 
 
  
 
III 
ZUSAMMENFASSUNG 
Die heterogene Gruppe der Myopathien kann sowohl die Funktion des Muskels beeinflussen, als auch 
verschiedene andere Organsysteme des Körpers, wie zum Beispiel das Bindegewebe, das Herz oder 
die Lunge.  Erkrankungen der Skelettmuskulatur können entweder erworben oder vererbt sein und die 
korrekte Diagnose der Erkrankung ist aufgrund von Ähnlichkeiten der Symptome oft schwer zu stellen. 
Daher sind neben der Patientenanamnese, sowohl weitere laborchemische Tests, als auch eine 
Muskelbiopsie äußerst hilfreich. Durch neue Erkenntnisse und Einsatz neuer Analysemethoden ist die 
Klassifikation der Myopathien daher in einem dauerhaften Wandel.  
Die erworbenen Muskelerkrankungen sind theoretisch behandelbar, jedoch stehen zumeist nur sehr 
unspezifische Behandlungsoptionen zur Verfügung. Im Gegensatz dazu, sind für vererbte Formen der 
Muskelerkrankungen bisher keine kausalen Therapiemöglichkeiten bekannt, jedoch ist auch hier die 
Entwicklung neuer Therapien von größter Bedeutung um sowohl die Lebensqualität, als auch die 
Lebenserwartung der Patienten zu verbessern. Um dies zu erreichen, ist das Wissen über die 
zugrundeliegenden pathologischen und immunologischen Mechanismen von großer Bedeutung. 
Durch ihre multifunktionalen Eigenschaften sind Makrophagen nicht nur an verschiedene Reaktionen 
im Muskel beteiligt, sondern es wurde auch gezeigt, dass sie eine wichtige Rolle bei Verletzungen der 
Skelettmuskulatur spielen. Neben ihrer Rolle bei der Entfernung von Pathogenen, wurde gezeigt, dass 
Makrophagen hier von einem pro-entzündlichen zu einem eher alternativ aktivierten Phänotyp 
wechseln. Des Weiteren sind sie wichtige Mediatoren von Autoimmunreaktionen im Muskel und 
könnten daher ein interessantes Ziel für zukünftige Therapien sein. 
In der vorliegenden Arbeit wurden drei verschiedene Muskelerkrankungen untersucht. Alle Entitäten 
zeigen entzündliche Phänomene, zeichnen sich zusätzlich aber durch spezifische immunologische 
Phänomene aus. Gemeinsam ist ihnen ein jeweils charakteristischer Einstrom von Entzündungszellen 
in den Muskel und das angrenzende Bindegewebe. Die Zusammensetzung dieses Zellinfiltrates war 
jedoch bei den verschieden Erkrankungen unterschiedlich und die Beteiligung von z.B. Lymphozyten 
oder Makrophagen war unterschiedlich stark ausgeprägt. Weiterhin unterscheidet sich das zugrunde 
liegende Zytokinmilieu innerhalb des Muskelgewebes und dieses ist höchst spezifisch für die 
einzelnen untersuchten entzündlichen Myopathien und die Muskeldystrophie. Daher war es Ziel der 
Arbeit, die genauen Interaktionen zwischen den Immunzellen zu untersuchen, sowie die 
charakteristischen Phänomene der Erkrankungen (z.B. Hypoxie, Entzündung und Fibrose) zu 
untersuchen. 
 
Nekrotisierende Myopathie können sowohl durch eine immun-vermittelte Genese, als auch durch 
Kontakt mit toxischen Substanzen ausgelöst werden. In der vorliegenden Arbeit konnte gezeigt 
werden, dass beide Subgruppen klar durch morphologische Kriterien, als auch durch spezielle 
Immunaspekte, wie beispielsweise das Vorkommen von Autoantikörpern, B Zell-Invasion, als auch 
das zugrunde liegende Zytokinmilieu, gekennzeichnet sein. Die Immunreaktion von Patienten mit 
immun-vermittelter Genese war weiterhin gekennzeichnet durch ein TH1-basiertes, pro-entzündliches 
Milieu mit erhöhter Expression von IFN-γ und TNFα. Interessanterweise wiesen beide Gruppen, neben 
  
 
IV 
Muskelfasernekrosen, klar definierte entzündliche Zellinfiltrate mit Makrophageninvasion in das 
Muskelgewebe auf. Makrophagen waren dabei die vorherrschende Zellpopulation und im gesamten 
Muskel verteilt. Des Weiteren fanden sich in den Infiltraten CD4+ und CD8+ T Zellen bei Patienten mit 
immun-vermittelter Genese. Bei diesen Patienten waren jedoch selten B Zellen oder Plasmazellen im 
Muskelbiopsat zu finden und die Expression des B Zell Chemokins CXCL13 war gering. Auch konnte 
eine klare Expression von MHC Klasse I Molekülen und eine Ablagerung von Komplement gefunden 
werden, während Patienten mit einer toxischen Genese keine dieser Merkmale aufwiesen. Daher 
können die Subgruppen mit nekrotisierender Myopathie klar voneinander abgegrenzt werden. 
Die Analyse des klinischen und morphologischen Bildes von Patienten mit Dermatomyositis zeigte, 
dass juvenile Patienten im Gegensatz zu adulten Patienten, sehr charakteristische Symptome 
aufwiesen, wie beispielsweise Schluckbeschwerden und Kalzifizierung der Skelettmuskulatur. 
Andererseits werden beide Erkrankungen als entzündliche Vaskulopathie eingestuft, wobei eine 
genuine Zerstörung der Gefäßwände nicht vorliegt. Ein typisches perifaszikuläres Atrophiemuster 
konnte ebenso wie hypoxische Effekte identifiziert werden, wobei beide Phänomene deutlich 
ausgeprägter bei juvenilen Patienten vorkamen. Da die hypoxischen Veränderungen meist im 
Perimysium auftraten, sowie in den angrenzenden Fasern, wurden diese Bereiche mittels 
Laserdissektion ausgeschnitten und im Anschluss per qPCR analysiert. In diesen Bereichen konnte 
eine Hochregulation an Hypoxie-assoziierten Molekülen gefunden werden, während die zentralen 
Bereiche des Gewebes derselben Patienten keine verstärkte Expression aufwiesen. Passend zu 
diesen Ergebnissen konnte ein Verlust von Kapillaren gemessen werden. Die Quantifizierung der 
Kapillaren pro Faser hat gezeigt, dass der Kapillarverlust bei juvenilen Pateinten verstärkt vorkam. 
Dies zeigt, dass Hypoxie bei der Entwicklung der perifaszikularen Atrophie beteiligt ist, und dass die 
beschriebenen Effekte besonders bei juvenilen Patienten vorkommen. 
Einige erbliche Myopathien können ebenfalls signifikante entzündliche Infiltrate aufweisen, wie 
beispielsweise die Muskeldystrophie Duchenne. Die Entwicklung von Fibrose in der Skelettmuskulatur 
ist dabei ein Hauptkriterium der Muskelfaserdegeneration und korreliert direkt mit einem frühen 
Gehverlust. Die Färbung mit EvG und Kollagen VI zeigte diese Fibroseentwicklung und 
Expressionsmolecule wie beispielsweise TGFβ oder die Kollagensynthetase (P4HA1) waren 
signifikant erhöht im Vergleich zu gesunden Kontrollen. Makrophagen sind in Entzündungsprozessen 
involviert und kontrollieren außerdem fibrotische Prozesse. In der vorliegenden Arbeit konnte gezeigt 
werden, dass sich sowohl Entzündung, als auch fibrotische Prozesse charakteristisch verändern. Die 
Quantifizierung der Makrophagen zeigte, dass die stärkste Zellinvasion bei Patienten mit einem Alter 
von vier Jahren gesehen wurde. Im Gegensatz dazu sind die Entzündungsprozesse nach dem Verlust 
der Gehfähigkeit rückläufig. Diese Veränderungen sind durch verminderte Zahlen an 
Entzündungszellen, sowie durch reduzierte Expression von Molekülen die Entzündungsprozesse 
vorantreiben gekennzeichnet. Ein neu entwickelter computer-basierter Algorithmus wurde dabei 
genutzt, um die Entwicklung der Fibrose zu quantifizieren. Die Menge an Bindegewebe steigt mit dem 
Alter der Patienten, während bei älteren Patienten außerdem ein fettgewebiger Umbau ein wichtiger 
Aspekt der Pathologie war. Die Quantifizierung zeigte weiterhin, dass das Verhältnis zwischen Fasern 
und Bindegewebe bei Patienten mit Muskeldystrophie Duchenne im Vergleich zu Muskeldystrophie 
Becker und weiblichen Überträgerinnen des mutierten DMD Gens reduziert ist. 
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1 INTRODUCTION 
Entities of the heterogeneous group of myopathies not only affect the skeletal muscle, as well as the 
connective tissue, but also the cardiac muscle, the respiratory system, the skeleton, the skin and a 
multitude of other organ systems. This may give rise to rather mono-symptomatic diseases, but also to 
complex ‘system diseases’. Myopathies can either be inherited (recessive, dominant, e.g. muscular 
dystrophies) or acquired (e.g. autoimmune diseases, exposure to toxins etc.). Even though 
myopathies are in general relatively rare, they comprise a huge variety of subgroups, adding up to 
more than 800 different forms of neuromuscular diseases (classification according to Walton). 
Exceptions to the exceedingly rare forms are inherited myopathies, like the Duchenne muscular 
dystrophy (DMD), with an incidence of about 1:5.000 male new-borns. 
Theoretically, acquired myopathies are treatable, but there are often only non-specific therapeutic 
options, and some forms of myopathies are completely resistant to therapy (with e.g. corticosteroids). 
In contrast to acquired myopathies inherited forms of myopathies are not curable with current 
medication; nevertheless, treatment is warranted to increase the life expectancy and quality of life. To 
understand the natural course of these diseases, the knowledge of underlying pathological and 
immunological mechanisms is highly important. 
 
1.1 Autoimmune processes and skeletal muscle diseases 
A number of inflammatory diseases of the skeletal muscle were termed immune inflammatory 
myopathies (IIMs). These comprise the so called classical entities dermatomyositis (DM), polymyositis 
(PM), necrotizing myopathy (NM) and sporadic inclusion body myositis (sIBM), which are discussed in 
more detail below. However, the contribution of an autoimmune pathogenesis to these entities is much 
debated. Especially in sIBM, two pathomechanisms are concurring, inflammatory processes and 
degenerative processes, and it is to date not clear, which one is the first process and which one is a 
subsequent event. On the other hand, an autoimmune pathogenesis is generally accepted for the 
entities DM and autoimmune NM. To understand the underlying immunology of myopathies and the 
cells involved in these complex mechanisms is highly important, since it is the prerequisite for 
development of new and targeted therapies.  
In general, autoimmunity is defined as an attack by cells of the immune system, which is directed 
against their own cells or organs instead of foreign cells 1. The underlying pathomechanisms of 
autoimmunity are under intense investigation and are very complex, involving a multitude of different 
cells of the immune system. Examples for autoimmunity are rheumatoid arthritis, lupus erythematodes, 
Wegener´s granulomatosis or the Sjögren´s syndrome.  
For understanding the specific diagnosis and also treatment options of these autoimmune muscle 
diseases, the detection of autoantibodies is crucial. A causative link has been established to the 
pathogenesis of certain myopathies 2. It is possible to identify certain autoantibodies which are linked 
to specific diseases makes it very likely that autoimmunity plays a major role in their pathogenesis. 
Furthermore, recognition of autoantibodies serves as s diagnostic tools. To give an example, anti-
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signal recognition particle (SRP) antibodies have been identified in a subtype of autoimmune NM. 
Although their role in myopathies is not clear, but it was recently shown that their levels directly 
correspond to disease activity and also paralleled the creatine kinase levels in affected patients, thus 
their monitoring serves as a very useful tool to monitor therapeutic efficiency 3. Some of the most 
commonly found antibodies in the entities, which are also investigated in the current study, are 
summarized in Table 1. Beside this intrinsic involvement of autoimmunity, also e.g. 
immunosuppressive medication can lead to immunodeficiency and a subsequent shut down of the 
immune mechanisms 4,5, resulting in possibly considerable complications, such as opportunistic 
infections. 
 
Table 1: Most common autoantibodies in necrotizing myopathy and dermatomyositis  
Entity Disease associated 
Necrotizing myopathy HMG-CoA, SRP, Jo1, PL-7, PL-12, Ro52 
Dermatomyositis Mi-2, Jo1, p155/140, MDA5, PM-Scl 
 
To classify autoimmune diseases a general organization depending on the involved organs or organ 
systems is used. Hence, diseases are grouped into organ-specific ones, such as multiple sclerosis or 
myasthenia gravis, or into those comprising systemic involvement, e.g. rheumatic arthritis or Sjögren´s 
syndrome. 
In autoimmunity, a correlation to genetic predisposition, as well as to environmental triggers is 
assumed 6,7. Regarding the genetic predisposition, studies with twins revealed that there is a high 
variation of a genetic association in different autoimmune diseases and that further research is needed 
to pin down specific involved genetic molecules 8. In addition, genome-wide search studies found 
correlations of gene variations which are related to diseases 9. Many studies showed especially the 
importance of the human leucocyte antigen (HLA) gene complex, e.g. HLA- DQA1*0301 in DM 10,11 or 
HLA-DRB1*01 in macrophagic myofasciitis 12. Nevertheless, genetic predisposition seems to be only a 
minor factor for development of autoimmune diseases and environmental triggers may be involved 
frequently 13. Dysregulation of the immune system in reaction to toxins or pathogens can initiate an 
inflammatory response mainly leading to activation of T cells. The starting signaling cascade then 
leads to immune reactions with antibody production and tissue injury 14. To date, numerous studies 
have conclusively demonstrated that autoimmune reactions/diseases are induced by various toxins 15. 
Interestingly, autoimmune processes have also been discussed to be involved in the pathogenesis of 
genetic disorders of the skeletal muscle like Duchenne muscular dystrophy. Mendell et. al. have 
shown that autoreactive T cells directed against revertant fibres in this disease 16. The authors argue 
that truncated or dysfunctional dystrophin protein is recognized as ‘non-self’ and therefore elicits an 
autoimmune response. However, it remains to be established if this happens as a regular 
phenomenon in all of the affected boys and if this autoimmune response is somehow silenced during 
the disease course. Although not part of the present thesis, it needs to be stressed that these 
questions will certainly be addressed and will be important in future therapeutic options.  
INTRODUCTION 
 
- 3 - 
1.1.1 Macrophages 
The bone marrow gives rise to haematopoietic stem cells (HSC), differentiating into monocytes, which 
reside in various lymphoid and nonlymphoid tissues (e.g. liver: Kupffer cells, lung: alveolar 
macrophages), but can also circulate in the body’s blood stream. Macrophages are distinguished by 
their morphology and specialized functions. Furthermore, some specialized monocytes, as microglia in 
the central nervous system (CNS) are not regenerated via bone marrow derived cells but probably 
renew themselves from local resident cells. 17,18 (Figure 1 A) 
Macrophages are involved in steady-state homeostasis, where they phagocytose or engulf cellular 
debris and dying cells 19. Via receptors like the scavenger receptor or CD14, pathogens are 
recognized and phagocytosis is initiated. The debris is actively encapsulated into phagosomes, which 
are acidophil. To further digest cellular debris/pathogens, the phagosome fuses with lysosomes 
containing enzymes and proteins for cell lyses. Lysozyme, toxic free radicals and the acid milieu 
subsequently digest the debris. In response to inflammation, macrophages stimulate lymphocytes via 
secretion of cytokines 19–21 and stimulate tissue fibrosis and wound healing 22. Each of these functions 
is later discussed in more detail. 
 
Figure 1: Macrophage development and function 
A: Development of macrophages from hematopoietic stem cells and their differentiation into tissue-resident cells; 
B, C: Polarization of naive macrophages is dependent on external stimuli. B: Classical activation of macrophages 
(M1) after LPS or IFN-γ stimulation and C: alternative activation of macrophages (M2) through stimulation with IL-
4 or IL-13. The figure is adapted for A: from Geissmann et. al. Science, 2010 19 and for B, C: from Biswas & 
Mantovani, Nature Immunology, 2010 23 
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Depending on their function and expression profile, macrophages are divided into different subsets, 
but the exact definition of these phenotypes is controversially discussed. The polarization of 
macrophages is not a straight forward development; on the contrary, it has been reported that various 
intermediate macrophage phenotypes exist and changing stimuli might redirect macrophage 
polarization. Hence, macrophages are probably not terminally differentiated, instead they show a gene 
expression, which is linked to environmental triggers und stimuli. 18,24–31 The two main subclasses of 
macrophages are the classically activated macrophages (CAM, M1, Figure 1 B), which act pro-
inflammatory, and the alternatively activated macrophages (AAM, M2, Figure 1 C) 32, which react more 
anti-inflammatory. In addition, certain ‘disease-associated’ macrophages and ‘regulatory’ 
macrophages exist 20. Each subgroup plays an important and partly opposing role in immune 
responses and tissue homeostasis and might actively contribute to development or progression of 
disease, e.g. in promoting tumor angiogenesis 33–36 or in enhancing the process of liver fibrosis 22. 
 
Classically activated macrophages are generated after IFN-γ− or LPS-induction by T helper cell 1 
(TH1) stimulation and STAT1 signalling to regulate the cellular immune reaction against pathogens and 
are involved in early resolution of inflammatory processes. They are able to produce high amounts of 
pro-inflammatory cytokines (e.g. IL-12, IL-1β or TNFα) and mediators such as reactive oxygen 
species. Molecules like IL-12, iNOS and COX are therefore used to classify macrophages as CAMs. 
Since these species are also be harmful for neighbouring healthy tissue, the reaction of these 
macrophages needs to be controlled to prevent extensive tissue damage by e.g. down-regulation of 
their pro-inflammatory activity through AAMs. 20 
In contrast to CAMs, AAMs are stimulated through a TH2-induced signalling via IL-4 or IL-13. They up-
regulate CD206, CD301 and MHC class II molecules, and secrete factors such as TGFβ and VEGF. 
AAMs have first been studied in worm and parasite infections, as well as in allergic reactions, but they 
also participate in humoral immune responses and tissue repair. The activation of genes in AAMs is 
mediated through the common IL-4Rα chain and STAT6 signalling. 30,37,38 
Both subgroups can further be regulated simultaneously or subsequently by the same factors, e.g. as 
it has been shown in mice, where adenosine is down-regulating CAMs, while at the same time AAMs 
are up-regulated 39. Current transcriptome analyses add significantly to the knowledge about the 
expression of various factors in human macrophages and identified for example new gene clusters, as 
well as new CAM- or AAM-associated cell surface molecules 36. 
 
To study macrophage activity and their function in human immune responses is challenging. It is not 
easy to obtain a macrophage cell line with remained macrophage profiles from tissue-resident 
macrophages, because isolating cells from the tissue might influence cell activity or activation. 
Therefore, studies are mostly performed on isolated monocytes primed with different stimuli. Mouse 
studies on the other hand are also intensely studied, but results are often hard to translate into the 
human system. 32  
For example, the role of arginine in mouse and human macrophages is highly discussed. The 
importance of the enzyme arginase and therefore the metabolisation of L-arginine to L-ornithine and 
urea in mice has been shown in various studies, e.g. the expression of inducible nitric oxide synthase 
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(iNOS) in mice 40,41. On the other hand, its relevance in the human situation is questionable 41–43. The 
same is true for the discussion of the role of expression of arg1, which is found in mouse 
macrophages and neutrophils and is an important mediator of T cell differentiation and macrophage 
priming into an alternative activation status 40. In contrast, arg1 is only expressed in human neutrophils 
and not in macrophages 42. Nevertheless, it is supposed to be involved in the repair of the extracellular 
matrix 18,44, but seems to be no suitable molecule for macrophage classification in humans. 
Various other processes are also associated with macrophage polarization, e.g. macrophages 
accumulate in obesity and secrete pro-inflammatory cytokines. In this disease the transition from anti- 
to pro-inflammatory macrophages promotes insulin resistance 45–48. Beside their protective functions, 
macrophages are also involved in the pathogenesis of respiratory diseases such as asthma or in 
chronic obstructive pulmonary disease (COPD). The quantities between different macrophage 
subtypes is influencing the course of the disease, since CAMs in moderate asthma are less numerous 
than AAMs, but the number of CAMs in severe forms of asthma is strongly increased 49. 
 
1.1.2 Macrophages in muscle diseases 
In human skeletal muscle, macrophages are essential, since they contribute to the immune reactions 
and are potent regulators of distinct pathological reactions. For the investigated groups of muscle 
diseases, the processes of hypoxia and fibrosis are of special interest, as well as the regeneration of 
skeletal muscle.  
 
Insufficient oxygen supply within the tissue is called hypoxia. It may be caused by pulmonary 
diseases, heart failure or different forms of vasculopathy and affects single or multiple tissues 50–54. It 
has been shown in humans and mice that macrophages accumulate in areas of low oxygen and 
changes in the oxygen supply lead to distinct changes in macrophage gene expression. The up-
regulation of genes involved in macrophage surviving/migration (e.g. VEGF, MIF) or in recruitment of 
other cells 55 affects the polarization of macrophages 56. In addition, expression of various 
cytokines/chemokines is influencing the polarization by e.g. exertion of pro-inflammatory phenotypes 
through increased expression of the macrophage migration inhibitory factor (MIF) has been shown in 
acute respiratory distress syndrome 57. Inflammation, healing of wounds and bacterial infections or 
tumors 58 can also cause hypoxia within the respective tissue. Many of the hypoxia-associated genes 
are regulated by the hypoxia-inducible factor 1 alpha (HIF-1α) and directly influence the efficiency of 
macrophages 56. The vasculopathy in DM results in hypoxia, therefore this entity is a good example for 
macrophages reacting to hypoxic stress and changes in macrophage gene regulation is a crucial 
feature to investigate. 
 
A further important aspect is development of fibrosis, which may be involved in very diverse cellular 
reactions as tissue remodeling, wound healing and replacement of specific mesenchymal tissue. It is 
mainly driven by AAMs and fibroblasts. The communication between macrophages and fibroblasts 
normally regulates wound healing and enhances fibrogenesis, but under varying conditions 
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macrophages may also cause reduced fibrosis 29. In different fibrotic diseases, like idiopathic 
pulmonary fibrosis, systemic sclerosis or DMD, fibrosis is one of the predominant pathologies. The 
process of fibrosis can theoretically be targeted by specific therapy. 
Depending on their phenotype and external stimuli macrophages react pro- or anti-fibrotic 59–61. 
Activated macrophages promote fibrosis by secretion of cytokines such as TGFβ or IL-1β and 
stimulate fibroblast proliferation and survival. As it was shown in liver fibrosis blocking of those 
macrophages slow down the disease process 59,62. In contrast, stimulation of the immune response 
additionally enhances fibrosis via secretion of anti-inflammatory cytokines and polarization of 
macrophages into wound healing phenotypes.  
Since activation of fibrosis is necessary for wound healing, but overactive processes also lead to 
negative effects in various diseases, anti-fibrotic therapy could contribute to slowing down the 
progress of disease. Thereby the challenge is to identify the point of time for administration, since 
activation of macrophages at varying stages can be either helpful or detrimental 22,59,62. Therefore, the 
timeline of action in the specific entity and the involved mediators are of high importance. A good 
example is DMD, where macrophage activation and polarization is time-dependent. 
 
1.2 Skeletal muscle 
Muscles can be categorized into three major subtypes, namely cardiac muscle, smooth muscle and 
skeletal muscle. While the movement of cardiac and smooth muscle (e.g. intestinal organs, blood 
vessels) is involuntarily, function and activity of the skeletal muscles are controlled by the central and 
the peripheral nervous system and are necessary for active movement of the body.  
 
1.2.1 Structure and function of the skeletal muscle 
During development, the long, cylindrical, multinucleated myofibres (muscle cells/muscle 
fibres/myocytes) are formed from progenitor myoblast cells through the process of myogenesis. The 
muscles of the extremities are anchored to the bones by tendons on each end. 
The functional basis for muscle contraction are repeated actin and myosin filaments, so called 
sarcomeres, which can contract to reduce the muscle length (Figure 2). Thousands of myofilaments 
form myofibrils, which in turn build up myofibres. They are located in the sarcoplasm (= cytoplasm) 
and are encased by collagenous connective tissue, the endomysium, when coating a single fibre, and 
perimysium, when the tissue is located around a whole muscle bundle. The myofibrils are laminated 
with mitochondria and myonuclei are located close to the sarcolemma (= plasma membrane). 
Furthermore the fibrils are surrounded by a sarcoplasmic reticulum, which serves as calcium reservoir 
for the muscle contraction. The contraction of actin and myosin is due to the regulatory proteins 
troponin and tropomyosin, which are associated with actin. After stimulation, initiated by the motor 
neurons and transmitted by peripheral nerves to the motor endplate, calcium ions (Ca2+) are released 
from the sarcoplasmic reticulum and troponin/tropomyosin undergo conformational changes to expose 
actin and facilitate the interaction with myosin. The contraction of the muscle is ATP-dependent. The 
energy is produced through an aerobic process in the mitochondria from carbohydrates or fat, or 
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anaerobically via glycolysis. Furthermore, to some extent ATP is also stored in the muscle and can be 
quickly released for muscle contractions. A major factor of this reaction is creatine kinase (CK), which 
catalyzes the conversion of ADP and phosphocreatine to creatine and ATP, restoring the energy 
source in muscle cells. 
 
The skeletal muscle fibres can be divided into so called slow twitch and fast twitch fibres. The type I, 
slow twitch, red fibres are packed with mitochondria and myoglobin. The contraction is slow, with little 
force and lasts for a long time. The type II, fast twitch, white muscle fibres, contract much faster and 
generate high power. But in contrast to the slow fibres they fatigue rapidly. 
To distinguish between slow and fast muscle fibres the staining with ATPase is quite common. In 
addition the determination of the myosin heavy chain (MHC) type of the fibre (MHC fast, slow, 
neonatal or developmental, various subtypes) is helpful. Healthy muscles contain a mixture of fibre 
types, and their proportions between muscles and between species vary. A type I fibre is surrounded 
by type II fibres and vice versa, producing a checkered pattern in the healthy muscle.  
 
Figure 2: Organization of skeletal muscle, figure from W. Whiting and S. Rugg, 2005, Dynatomy 
 
1.2.2 Interaction of skeletal muscle with other cells 
Besides their function in movement and body stability, the cross-talk of muscle cells with other cells of 
the body is intense. Various immune cells reside within the muscle and can react to environmental 
changes. They are also active in repair mechanisms or secrete growth factors. Especially 
macrophages are important for the clearance of debris after muscle injury, but also the influx of other 
immune cells is necessary. For these processes a functioning cross-talk is vital and cells need to be in 
close contact to coordinate the reactions inside the muscle 63. 
In case of injury or inflammation a well-orchestrated cascade is initiated. First, muscle cells secrete 
e.g. cytokines and chemokines (also termed myokines) which attract monocytes to the site of 
inflammation 64–66. Accumulated monocytes, as well as resident cells are activated, resulting in the 
secretion of additional attracting factors. In addition to local accumulation, myokines can circulate in 
the body and reach other tissues. When the muscle is exercised, IL-6 is induced and influences 
glucose production 64. After activation, the receptors for IL-1 or IFN-γ, as well as CCR2 and CCR4 are 
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also strongly up-regulated in muscle cells 67, hence leading to an expression of pro-inflammatory 
mediators such as TNFα or IL-1β. Following the activation of cells and a local pro-inflammatory phase 
a variety of myokines are released. After the ‘resolution’ of the inflammation, muscle regeneration is 
initiated, a crucial mechanism which involves differentiation of satellite cells and growth to myoblasts 
29,68. These myoblasts then fuse to myotubes and further differentiate to myofibres. For these 
processes of regeneration the switch from CAM to AAM is highly important, since CAMs are pro-
inflammatory and stimulate the first resolution of inflammation (till around 2 days after injury), while 
AAMs support muscle regeneration and growth (from 2 days after injury on) 29,69,70. In this context is 
has been reported that impaired generation of anti-inflammatory macrophage phenotypes lead to 
reduced regeneration rates 71. In addition, endothelial growth factors such as IGF-1 and VEGF are 
essential for angiogenesis. Moreover, satellite cells and macrophages are also important producers of 
these factors, again demonstrating their involvement in muscle repair 72. The continuously repetitive 
cycle of damage, repair and fibrosis in myopathies may lead to satellite cell exhaustion and fibre 
degeneration 68,73 as well as insufficient tissue remodeling. Therefore, targeting involved immune cells 
might be a strategy for modulating the course of disease. 
 
1.3 Myopathy 
According to the definition by the World Health Organization, myopathy is defined as a primary 
disease of the skeletal muscle that leads to a dysfunctional static. The different forms of myopathies 
are formally classified according to the ‘International Classification of Diseases’ and are divided into 
primary myopathies, other myopathies and myopathies with other underlying diseases (ICD: 
International Statistical Classification of Diseases and Related Health Problems; current version: ICD-
10).  
 
1.3.1 Diagnosis 
To accurately diagnose a patient with myopathy various criteria are important. Acquired and inherited 
myopathies may display similar symptoms, but a correct diagnosis is of outmost importance for the 
decision on an adequate treatment 74. 
Next to careful examination of the patient other points, like a complete clinical history, additional 
symptoms (e.g. cardiac involvement, involvement of other organs) and localisation of the affected 
muscle (via e.g. MRI - magnetic resonance imaging) should be considered.  
Nowadays, muscle biopsies are less often performed, since an increased understanding of the 
underlying mechanisms and the development of new techniques (e.g. whole genome sequencing) 
make them less vital. Especially inherited muscle diseases are sometimes only identified via genetic 
techniques. Nevertheless, biopsies of ‘skeletal muscle’ are of outmost importance to get a detailed 
diagnosis. The same is true for conditions where the underlying gene is not identified yet. 
Furthermore, the expression pattern of certain relevant proteins involved in pathogenesis can be 
determined on muscle sections. With histology, enzyme and immune histochemistry and electron 
microscopy it is possible to identify structural abnormalities and a multitude of pathological processes. 
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1.3.2 Symptoms 
A classical symptom of all myopathies is muscle weakness, but the distribution can strongly vary 
between different entities or single patients with the same entity. Further symptoms are stiffness, 
muscle atrophy or swelling, as well as cramps or myalgia. Problems with walking long distances, 
climbing stairs or difficulties with swallowing and speaking are described by the patients. Additionally, 
symptoms may be very complex, further affecting other organ systems as the heart, lungs or the skin. 
However, for each entity disease-characteristic symptoms have been defined and described.  
The investigation of the serum may be helpful as well, because increased CK levels, lactate levels, 
liver enzymes etc. and/or elevated antibody titers are helpful. For some subgroups of myopathy 
autoantibodies are found and may be characteristic, although their precise pathogenetic relevance is 
still unclear in inflammatory myopathies. The muscle-related symptoms can arise through e.g. allergic 
reaction, side effects of drugs or exposure to toxic substances and previous autoimmune diseases 
trigger a secondary inflammatory reaction inside the muscle.  
 
1.4 Idiopathic inflammatory myopathies (IIM) 
Idiopathic inflammatory myopathies classically comprise three ‘related’ entities, which are Polymyositis 
(PM), Dermatomyositis (DM) and sporadic Inclusion body Myositis (sIBM). Recently IIMs have been 
extended by two further entities, which are the non-specific myositis 75 and the necrotizing myopathy 
(NM)/necrotizing autoimmune myopathy (NAM) 76. Additionally, further reclassifications are constantly 
discussed 77,78 and the definition of specific entities, e.g. PM is not consistent 79–81. With an incidence 
of 5-10 per 100,000 IIMs outnumber other rare inflammatory myopathies like eosinophilic myofasciitis, 
granulomatous myositis, focal myositis or macrophagic myofasciitis.  
The five groups of IIMs share classical symptoms such as myalgia, muscle weakness and 
inflammatory infiltrates, however each group is also characterized by specific clinical and 
morphological features 77,80,82. In some patients, myositis-associated (MAA) or myositis-specific 
autoantibodies (MSA) can be found. 
 
The treatment of IIMs mostly includes medication with corticosteroids and physical therapy 76,82. The 
efficacy varies between the groups. While DM and PM show relatively good responsiveness to 
immunosuppressive therapies, sIBM generally displays a slower development of symptoms and shows 
no substantial response to immunosuppressive therapy 74,83–88. Most treatment regimens were not 
even tested in a controlled and randomized/standard fashion. They are often used in analogy to other 
treatment regimens for defined, presumably related inflammatory autoimmune diseases. This fact 
makes discussion and consensus description about effectiveness of ‘new’ options difficult and 
controversial. 
 
1.4.1 Necrotizing myopathy (NM) 
In recent years, patients with necrotizing myopathies 83,89 have been thoroughly described and 
discussed 90 and based on pathological criteria of immune and inflammatory myopathies 76 NM was 
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added to the conventional IIMs. In this classification, immune-mediated NM (IMNM) was described as 
an immune polymyopathy, whereas unique morphological features are mentioned. The most important 
criteria for diagnosis were myofibre necrosis, regeneration and a poor mononuclear cell infiltrate. 
Additionally, varying transsarcolemal major histocompatibility complex class I (MHC class I) positivity 
was described 91,92. In contrast to the IMNM group a second subgroup of NM was postulated where a 
toxic agent causes the disease 93. 
 
Patients with IMNM suffer from severe symmetrical proximal muscle weakness, myalgia, elevated 
serum CK levels and they show myofibre necrosis in their muscle biopsy 94. Additional symptoms are 
fever, cardiac or pulmonary involvement and weight loss may occur in some IMNM patients but not in 
toxic-mediated NMs. The specific skin rash as seen in dermatomyositis is absent in IMNM. As for the 
entities DM and PM, the determination of MSAs and MAAs is an important part of the diagnostic work 
ups, and recently some NM-specific antibodies were found 95–98. First, the detection of SRP-
antibodies, a ribonucleoprotein, should be mentioned, because a correlation between the severity of 
clinical symptoms, serum CK levels and the level of SRP autoantibodies was seen 3. Secondly, the 3-
hydroxy-3-methylguanyl-coenzyme A reductase (HMGCoA) antibody is of interest. The latter was 
found in a subgroup of immune-mediated statin-induced NMs (also termed statin-induced immune 
NAM) 99. Furthermore patients with anti-synthetase antibodies such as Jo1, PL7, PL12 or antibodies 
associated with paraneoplasia present a muscle pathology of NM 95,100–103. These findings are 
particularly relevant since they indicate that the inflammation in the muscle is a secondary event, 
which follows a primary immune reaction against e.g. a tumour 104.  
 
Under immuno-suppressive/-modulatory treatment, muscle symptoms decline, which further supports 
the significant involvement of immune reactions in development of disease 105,106. Since repetitive 
disease flares are frequent in NM, patients may develop strong reactions to the treatment with 
corticosteroids and therefore additional therapeutic options are mandatory 105,107–109. To date, 
methotrexate (MTX), intravenous immunoglobulins (IvIGs), plasma exchange and/or Rituximab are 
proposed, but are not evaluated in randomized controlled trials 108,110–112. In contrast to IMNM, patients 
with a toxic aetiology do not display any additional clinical or morphological signs of an immune 
reaction, despite the presence of typical necrotic myofibres and myophagocytosis. Only the removal of 
the triggering agent contains a therapeutic character 99,113.  
 
In a morphological context, various reports showed, that necrosis and myophagocytosis are 
predominant features in the muscle biopsies and that invading immune cells are found amongst the 
inflammatory infiltrate. These infiltrates mainly consist of macrophages and only few lymphocytes are 
found, whereas B cells are relatively sparse 75. Furthermore an up-regulation of the membrane-attack-
complex (C5b9) in muscle biopsies has been demonstrated, as was positivity for MHC class I on the 
sarcolemma. However, different authors reported other results for MHC class I and C5b9 expression 
98,106,108,114.  
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1.4.2 Adult and juvenile Dermatomyositis 
As part of the IIMs classical clinical symptoms of myopathies are found in dermatomyositis. These 
symptoms include weakness or pain, but in addition discriminating features, such as a very specific 
skin involvement is also common. The skin can show a characteristic rash on the décolleté, the eyelids 
and the cheeks, Gottron´s papules or calcifications on elbows and knees. 115 
The juvenile dermatomyositis (jDM) is the most common inflammatory myopathy in children with the 
incidence being 3-4/1,000,000 children. JDM is defined as DM with an onset of disease before the age 
of 16, with girls being more affected than boys 116–118. Comparable to the classical symptoms of adult 
DM (aDM), juveniles show the following symptoms: Joint pain, fatigue and dysphagia. However, some 
symptoms and signs of jDM are unique and are not found in aDM such as calcification of the skeletal 
muscle. In addition, the children withdraw from their environment and have a slightly elevated body 
temperature. In acute cases complications like arthritis, intestinal perforation, pneumonia, myo- and/or 
pericarditis, cardiac arrhythmias, kidney failure or CNS involvement with central vasculitis have been 
described. In these cases the fast start of an adequate treatment is crucial for prognosis and 
progression of the disease 119–121. Diagnostic evaluation comprises laboratory values, with the blood 
often showing increased CK values; even though the values can also be in the normal range. In about 
40 % of DM cases myositis-specific or -associated antibodies are detected 10,122 such as anti-Mi-2 or 
anti-PL12. Some of these autoantibodies display a correlation to the clinical development, which hints 
at a connection between antibodies and immunogenesis 123, e.g. Mi-2 autoantibodies have not been 
associated with cancer and indicate a rather ‘benign’ course of disease. 
  
For treatment, immune-modulating medication is used. Current steroid treatment, methotrexate (MTX) 
and intravenous gamma-globulins are combined. However, some patients need further therapy or 
treatment of drug-induced side effects. Anti-TNF antibodies or B cell blockers (e.g. Rituximab) have 
been used with varying success, but until today no double-blind studies have been performed to prove 
the efficacy of these treatments or concerning the molecular basis of the disease. 124–126 
 
Since the aetiology of DM is unclear, current studies address a broad variety of hypotheses 
concerning predisposition for and development of the disease. Amongst these, certain genetic 
predispositions 11, and a correlation with specific human HLA alleles were found (e.g. HLA-DRB1*03 or 
HLA-DQA1*0501) 11,127. Furthermore, an association with polymorphisms of the TNF gene, encoding for 
the pro-inflammatory TH1-related cytokine TNF-α, was suspected 128 and in jDM maternal microchimerism 
may be an influencing factor: During pregnancy, cells are exchanged between mother and child influencing 
biological processes of the foetus, and studies of Reed et al. show that children affected with jDM have 
higher amounts of maternal cells than their siblings. The cells were located within muscles and the 
peripheral blood 129 and are mostly either dendritic cells or B cells of the maternal peripheral blood 130. 
Moreover, some studies show a link to infection of e.g. the respiratory tract or gastrointestinal 
symptoms 117,131. Some studies focus on aspects of the immune response as the contribution of 
chemokines and cytokines, especially IFN-associated ones. It has been shown, that type I interferons 
e.g. IFN-α and IFN-β, are involved in the formation of tubuloreticular structures within endothelial cells 
and may be of diagnostic value 116,132. Furthermore, they promote various cellular functions that are 
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involved in DM pathogenesis, e.g. MHC class I expression 133,134 or T cell activation 135. Various genes 
regulated by type I interferons are up-regulated in jDM and aDM patients 136,137. Additionally, type II 
interferons may contribute to DM and were also focus of different studies 138. Other lines of research 
concentrate on the role of dendritic cells, especially plasmacytoid dendritic cells (pDC). These cells 
seem to be important for various reasons: first, they are a cellular source of huge amounts of type I 
interferons and second, mature cells are mostly located in the areas of lymphocytic infiltrates 139,140. 
Additionally, T and B cells are found as well as significant amounts of macrophages 141,142. However, 
the composition of various subtypes of inflammatory cells has not yet been precisely illuminated; 
neither have their specific contribution to certain pathomechanisms.  
On muscle biopsy, typical perifascicular atrophy is seen, as well as infiltration by immune cells into the 
perimysium and the adjacent muscle tissue. Today it is commonly accepted that this perifascicular 
muscle fibre atrophy and ischemia as a result of the vasculopathy, are hallmarks of the disease 
94,126,143,144. However, the contribution of each of these features and their interrelationship are not well 
characterized and source of controversies 135. By using 3D reconstructions Gitiaux and coworkers 
have elegantly shown that inflammation in larger arcade arteries may be more relevant to hypoxia-
related pathology than capillary loss 145. Various proteins were up-regulated on muscle fibres, which 
may have been a consequence to the hypoxic events. 
 
1.4.3 Animal models in immune inflammatory myopathies 
The use of animal models in the last years has increased our knowledge about various diseases and 
processes including myopathies 146–148. Unfortunately most of the latter, such as DM or NM, can still 
not be accurately modeled in the mouse until today. Instead most current mouse models only mimic 
single aspects of IIMs and accompanying systemic features are often not displayed. For example a 
mouse model, where a viral infection is leading to development of muscle symptoms (e.g. 
macrophage accumulation, complement activation in muscle cells), but no skin involvement, only 
mimics parts of the pathogenesis of DM 146,149. Another model to simulate PM is induced by 
immunization of mice with myosin, which led to infiltration of T cells and macrophages, but not of B 
cells 147.  
To investigate the various aspects of myopathies an animal model would have the advantage to 
modify molecular pathways that were identified as relevant, but developing of models is still ongoing.  
 
1.5 Muscular dystrophy (MD) 
In contrast to inflammatory myopathies, muscular dystrophies are caused by mutated genes, which 
lead to defective muscle proteins and accompanied by a subsequent degeneration and/or necrosis 
and death of cells/tissue. The major forms of muscular dystrophy are classically grouped into X-linked 
dystrophies (e.g. Duchenne muscular dystrophy, Becker muscular dystrophy, Emery-Dreifuss 
muscular dystrophy), limb-girdle muscular dystrophies (various autosomal dominant and recessive 
forms) and others (e.g. congenital, distal, myofibrillar, fascioscapulohumeral and myotonic muscular 
dystrophies).  
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Symptoms frequently arise in early childhood and are getting more severe over time. The diagnosis of 
muscular dystrophies is based on evaluation of muscle biopsies, protein analyses, 
electrocardiography and genomic DNA analyses. 150–153 The diseases manifest as multi-system 
disorders involving different parts of the body such as the heart, gastrointerstinal system, the 
peripheral nervous system or brain. Next to symptoms of a myopathy, common signs of the disease 
are scoliosis, cardiomyopathy 154,155 and respiratory difficulties156 .  
 
1.5.1 Dystrophin 
Muscular dystrophies can be caused by mutations of various proteins involved in the dystrophin-
glycoprotein complex (DGC) that provides structural stability to the muscle cell by connecting the 
sarcomeres to the muscle membrane (Figure 3). 
The gene DMD, which encodes for the dystrophin protein, is the largest known human gene and 
located on the short arm of the X-chromosome (Xp21.2). Mutations of dystrophin and subsequent 
disruption of the protein complex leads to progressive instability, fibre necrosis, inflammation, 
degradation and fibrosis. Some of these processes are linked to each other and may contribute to 
disease progression in DMD. Since the heart and respiratory muscles are also affected by muscle 
fibre loss, most of the patients die due to pneumonia or cardiomyopathy (approximately 10-40  % of all 
DMD patients 154,157).  
 
Figure 3: Organization of the dystrophin-glycoprotein complex 
BMD: Becker muscular dystrophy; CMD: congenital muscular dystrophy; DG: dystroglycan; DMD: Duchenne 
muscular dystrophy; LGMD: Limb girdle muscular dystrophy; NOS: nitric oxide synthase; picture from 
‘Pharmacological strategies for muscular dystrophy’ Khurana and Davies, Nature reviews 2008 158 
 
1.5.2 Duchenne muscular dystrophy (DMD) 
Duchenne muscular dystrophy is the most common form of the muscular dystrophies and worldwidely 
affects 1:5,000 male new-borns 94. The recessive X-chromosomally inherited disease leads to a non-
functional dystrophin protein followed by muscle necrosis, degeneration, fibrosis and a premature 
death. While both sexes can carry the gene mutation (60-70 % deletion, 15-30 % point mutations, 
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~10  % duplications) only males exhibit severe symptoms. In contrast, females rarely show any signs 
of the disease. Usually the symptoms appear before the age of three years and are often detectable 
during early infantile development. The first signs are proximal muscle weakness of legs and pelvis 
accompanied by a loss of muscle mass. The development of motor milestones is delayed and jumping 
or running is not possible at all. Eventually, weakness spreads and the symptoms grow stronger 
demonstrated by the classical Gowers´ sign 159. At the age of 10-12 years most of the boys are 
wheelchair bound due to the developing fibrosis of the skeletal muscle and subsequent muscle 
weakness. Steroid treatment can only delay these changes. Symptoms are enhanced by use of the 
wheelchair and scoliosis and bone deformation develop. At night assisted ventilation is often used and 
boys may be later dependent on constant respirator supply. Additionally, mild cognitive impairment 
can be found frequently 160, since dystrophin also has a neuronal isoform. The average life expectancy 
of patients before modern respiratory assistance was around 20 years, but due to improved supportive 
therapy, it increased up to 40 years or even older in the last decade. 
 
Treatment for DMD is mostly confined to supportive treatment of symptoms, which is of outmost 
importance and has been doubled the life expectancy. Since there is no direct cure for DMD until 
today, current therapies involve prednisolone or other corticosteroids, as well as the afore mentioned 
support of breathing, walking, orthopaedic- and physiotherapy. Consequently, new and more specific 
therapies are needed and various approaches are currently under investigation. One promising 
opportunity may be ‘exon skipping’, meaning skipping the mutated part of the gene, which results in a 
truncated but still functional dystrophin protein. However, clinical trials are currently beginning and the 
treatment may not be accessible worldwide and is probably only useful in a defined number of patients 
with specific gene mutations 161,162. Additionally, other pharmacological approaches 163,164 are under 
investigation and new targets are tested in mouse models. As an example, studies using a double 
mutant mouse model showed that restoration of 15-20 % of dystrophin can enhance the muscle 
strength and protect the muscle fibre from exercise-induced damage 165. Furthermore, increasing the 
muscle mass by insulin-like growth factors and improving calcium homeostasis 158,166 are goals of the 
research. Associated secondary processes, such as the role of mast cells 167 or the deregulation of the 
neuronal nitric oxide synthetase (nNOS) 168 are also of interest. 
 
It has been shown many times that immune inflammatory processes are strongly involved in the 
pathogenesis of DMD and that these processes are disease-specific. They are due to a dysregulation 
of inflammatory pathways, since it is clear that the influx of mononuclear cells and granulocytes occurs 
early in dystrophic muscles of mice 156,169,170. In addition to cellular influx, various cellular processes, 
e.g. endomysial fibrosis, are developing over time. Thereby, the amount of fibrosis within the muscle 
correlates with a bad outcome and an early loss of ambulation, which has been shown in a clinical 
study of DMD patients and a 10-year follow-up period. 171–174 Both processes, inflammation and 
fibrosis, and their interrelationship are not well understood and need to be investigated in more detail 
169. In some muscle biopsies so called ‘revertant’ fibres are found that by definition ‘re’-express the 
dystrophin protein. Alternative splicing leads to a shift inside the reading frame of the DMD gene and 
therefore a truncated but functional dystrophin protein can be detected 175,176. These fibres might be 
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targeted by immune cells 16. Up-regulation of utrophin in the sarcolemma, a homolog of dystrophin, is 
also characteristic in DMD patients. In this regard, mechanisms involved in up-regulation of utrophin 
and utrophin-associated genes is also currently under investigation 177 . 
 
1.5.3 Animal models of Duchenne muscular dystrophy 
In contrast to the other myopathies, where no appropriate animal models exist to date, in DMD, 
various animals are used to study the disease hallmarks. Although there are some distinctions 
between the mouse and human situation the mdx mouse is widely used as ‘standard’ model to 
analyse inflammation, fibrosis and new targets for therapy 178–181. In the mdx mouse, which carries a 
spontaneous genetic deficiency and is not genetically engineered, fewer/less severe symptoms occur 
and with increasing age the phenotype overall decreases 178. Since it was shown that utrophin 
diminishs the effects of dystrophin loss, the utrophin knockout mouse model is also used (utrn-/-) 182, 
even though, it is not directly a model of DMD. Other mouse models are the utrn-/-mdx double 
knockout or utrn+/-mdx heterozygous knockout mouse, where the development of disease is more 
similar to the human situation than in the respective single knockout. In these two mouse lines 
increased fibrosis and stronger clinical symptoms such as cardiomyopathies develop, and additionally, 
a reduced life expectancy is observed. 183,184  
Various projects underline the importance of DMD mouse models for the testing of new therapies and 
for increasing the understanding of involved processes. As an example, the arginine metabolism is 
under investigation, because arginine is often used as dietary supplement in DMD patients without a 
clear understanding of the long term effects. In mice, short-term treatments seem to be beneficial 185, 
but after a long-term use of arginine supplements, an increase of fibrosis due to an enhanced 
alternative polarization of macrophages was shown in mdx mice 186. In line with these findings the 
reduction of nitric oxide synthase (NOS) exacerbates muscle inflammation and fibre damage in mice 
187. Therefore, the competition and balance between both macrophage subtypes are of outmost 
importance in progression of disease in the mouse model 188,189. Furthermore, associated symptoms of 
DMD have to be studied. Since cardiomyopathy is one of the main causes of death, various groups 
have performed experiments to improve cardiac health. In this field Schinkel et. al. generated an 
adeno-associated virus to increase the expression of microdystrophin inside the heart and to protect 
intact cardiac morphology 190. 
 
Next to the mentioned mouse models, further model organisms are used to analyse the disease. 
There are various canine models, such as the golden retriever (GRMD), Rottweiler or German short-
haired pointer. The development of disease is comparable to that in humans and many of the 
characteristic features of DMD are found (e.g. fibrosis, regeneration, cardiomyopathy, respiratory 
distress). Additionally, a feline model of DMD exists, but the development of disease and its severity 
are different from that in the human situation. 178,191,192 
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1.5.4 Becker muscular dystrophy 
Becker muscular dystrophy (BMD) is a milder variant of muscular dystrophies (genetically allelic to 
DMD) caused by a reduced expression of dystrophin leading to a shortened but functional isoform of 
dystrophin. This muscular dystrophy is occurring in approximately 3 - 6:100,000 male new-borns and 
is therefore much less common than DMD.  
BMD patients mostly exhibit weak symptoms at an age of 10-25 years; however, there are highly 
variable courses of the disease. Some patients develop walking problems in their adolescence and 
others remain ambulant until their fifties or sixties 193. In addition, the life span of these patients may be 
reduced or in the normal range. The risk of sudden cardiac death due to cardiac insufficiency 
(hypertrophic cardiomyopathy) is higher and patients are also prone to develop rhabdomyolysis. In the 
muscle biopsy a reduced expression of dystrophin is found, whereas often only the N-terminal 
fragment of the dystrophin protein is affected. 
 
1.5.5 Female carrier of mutations of the DMD gene 
Apart from spontaneous mutations (~1/3 of patients 94) DMD and BMD are X-chromosomally inherited. In 
girls who carry the mutated gene, the normal, not-mutated gene can compensate for the affected one. 
Female carriers have a 50 % chance of passing the mutated gene on to their offspring 194 (Figure 4).  
The affected women are mostly asymptomatic but few (between ~3-8 %) can show symptoms in 
varying degrees 194. Those can be weak or range up to DMD-like symptoms including myalgia, 
elevated CK-levels, cramps and cardiomyopathies. 194 In the biopsy a mosaic pattern of dystrophin 
expression is found due to the scattered X-inactivation in the cells. 
 
Figure 4: X-linked recessive inheritance of the defective DMD gene 
Mother are carriers (fC) of the defective gene and statistically pass the disease to 50 % of her offspring. 
 
1.6 Aim of the project 
In the human body numerous and variable interactions occur between different key molecules of the 
immune system, such as lymphocytes or macrophages, and different tissues, including the connective 
tissue, blood vessels and the skeletal muscle.  
The aim of the study is the examination and morphological description of those interactions but also 
the analyses of specific and characteristic pathological phenomena, e.g. hypoxia or fibrosis. Since the 
latter features are hallmarks of distinct human muscle diseases, the human skeletal muscle is a 
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perfectly suitable system to study these various aspects and their interplay. In this work I have focused 
on specific disease entities that have an ‘inflammatory part’ in common. However they all exhibit 
different, but very specific features that can be described as pathological patterns (e.g. fibrosis, 
atrophy, necrosis, hypoxia …). These phenomena are suggested to be directly or indirectly linked to 
specific inflammatory processes. 
For the analyses of the entities different hypotheses were leading the investigation. In general, I 
assumed that macrophages hold an important role in the development and progression of all 
investigated diseases and therefore their role is addressed in detail.  
 
Hypothesis I: 
In the necrotizing myopathies acute immune processes lead to the development of disease in 
autoimmune NM in contrast to toxic NM. I postulate that it is possible to differentiate the immune 
response in the immune-mediated cases, compared to the toxic aetiology and that there are distinct 
subtypes. Lymphocytes and macrophages should be important in IMNM, while I expect only low 
numbers in nIMNM. I further assume that the different subtypes are distinguishable through their 
cytokine profile and that these can putatively serve as diagnostic tools to distinguish the different 
aetiologic backgrounds.  
 
Hypothesis II: 
Based on the well described morphological criteria for dermatomyositis and recent work about vessel 
organization, I investigated the severity of the hypoxia-related pathology. My particular interest is the 
effect of hypoxia on perimysial and centrally located muscle fibres in jDM in comparison to aDM. Since 
children are known to display a stronger phenotype of DM in comparison to adults, I expect to find 
differences with respect to inflammatory infiltrates and mechanisms of hypoxia. These results would 
also support the assumption, that inflammation and hypoxia are linked and that macrophages play a 
central part in both processes. 
 
Hypothesis III: 
The development of fibrosis describes a major feature of skeletal muscle degeneration in Duchenne 
muscular dystrophy. Since alternatively activated macrophages have been linked to fibrosis in several 
diseases, I assume that in DMD the influx and the amount of anti-inflammatory and wound-healing 
macrophages is stage-dependent. 
 
Little is known about the exact contribution of macrophages to these various pathomechanisms in 
human skeletal muscle diseases. However, the knowledge about molecular differences, especially 
concerning events in the progression and severity of the disease triggered by macrophages are of 
outmost importance. New insights on pathogenesis of the entities could create a way to find novel 
therapeutic approaches to treat inflammatory myopathies or muscular dystrophies.  
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2 MATERIAL 
2.1 Laboratory equipment, commercial kits and buffer 
 
Table 2: Laboratory Equipment 
Product Purchased from 
Agilent 2100 Bioanalyzer Agilent Technologies, USA 
PCR Cycler VWR, Germany 
PCR Cycler Eppendorf, Germany 
Kryostat HM560 Microm Laborgeräte, Germany 
Microplate Reader TECAN Infinite 200 Tecan, Germany 
Olympus BX50 Microscope & DP25 Camera Olympus, Japan 
Zeiss Observer.Z1 Microscope Zeiss, Germany 
Multifuge SR3+ Thermo Scientific, Germany 
Real-Time PCR System 7900 HT Applied Biosystems, USA 
Pannoramic 250  3DHistech, Hungary 
 
Table 3: Commercial kits  
Product Purchased from 
AEC Staining Kit (AEC101) Sigma-Aldrich, Germany 
BCA Protein Assay Kit Pierce, USA 
DNAfree Kit Ambion  Ambion, Germany 
High-Capacity cDNA Archive Kit Applied Biosystems, USA 
TaqMan Fast Universal PCR Master Mix (2x) Applied Biosystems, USA 
Liquid DAB+ Substrate Chromogen System DAKO, Germany 
PEN Membrane Glass Slides AlphaMetrix, Germany 
CapSure® LCM Cap AlphaMetrix, Germany 
HistoGene® LCM Frozen Section Staining Kit AlphaMetrix, Germany 
 
Table 4: Chemicals and buffer  
Product Purchased from 
Aceton Merck, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Germany 
Trizol Peqlab, Germany 
Glycogen Invitrogen, Germany 
Chloroform Merck, Germany 
Isopropanol Roth, Germany 
EtOH abs. Roth, Germany  
Citric acid Merck, Germany 
Elastica Solution ( resorcin fuchsin) Th. Geyer GmbH & Co. KG, Germany 
Eosin-Y Brunschwig Chemie, Netherlands 
Xylol Baker, Germany  
FCS (Fetal Calf Serum) PAA, Austria 
Nuclease-Free Water  Quiagen, USA 
Kernecht-Aluminium sulfate solution   Merck, Germany 
Lugol’s Solution Merck, Germany 
Mayers Hematoxylin Solution Merck, Germany 
Methyl violet  Merck, Germany 
Normal serum goat Vektor Laboratories, USA 
Normal serum mouse Jackson Immunoresearch, USA 
Normal serum rabbit Vektor Laboratories, USA 
ROTI-HISTOKITT II   Roth, Germany 
2. AK Kit Ventana/Roche, Switzerland 
Tissue Tek Thermo Sientific, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Germany 
Dulbecco’s Phosphate buffered saline (PBS) w/o Ca2+/Mg2+ Biochrom, Germany 
RPMI PAA, Austria 
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2.2 Antibodies 
 
Table 5: Antibodies used for immunohistochemistry  
Specificity Host Clone Dilution Purchased from 
αB-Crystallin mouse G2JF 1:10 Novocastra, Great Britain 
C5b9 mouse aE11 1:200 DAKO, Germany 
CD4 rabbit  SP35 undiluted ZYTOMED Systems GmbH, 
Germany 
CD8 mouse  144B 1:100 DAKO, Germany 
CD11c rabbit  EP1347Y 1:50 Abcam, Great Britain 
CD20 mouse L26 1:400 DAKO, Germany 
CD31 mouse  7C70A 1:25 DAKO, Germany 
CD45 mouse  2B11 1:400 DAKO, Germany 
CD56 mouse monoclonal 1:200 GeneTex Inc, USA 
CD68  mouse KP1 1:10,000 DAKO, Germany 
CD79a mouse 7CB117 1:100 DAKO, Germany 
CD138 mouse MI15 1:30 DAKO, Germany 
CD206 / MRC1 mouse 7-450 1:500 Acris, Germany 
CD301  mouse 125A10.03 1:200 Dendritics, USA 
Collagen VI mouse  VI-26 1:200 Merck, Germany 
Dystrophin  ascites fluid MANDYS8 1:10 Sigma-Aldrich, Germany 
Factor VIII rabbit Polyclonal 1:1000 DAKO, Germany 
HIF-1α mouse H1alpha67 1:40 Abnova, Taiwan 
iNOS  rabbit  polyclonal ready to use GeneTex Inc, USA 
Laminin-α5 mouse 4C7 1:30,000 Chemicon, Germany 
MHCneonatal mouse NB-MHCn 1:20 Novocastra, Great Britain 
MHC class I mouse W6/32 1:1000 DAKO, Germany 
MHC class II (anti-
HLA-DM) 
mouse CR3/43 1:100 DAKO, Germany 
Utrophin rabbit polyclonal 1:10 Sigma-Aldrich, Germany 
VEGF rabbit 15D2 1:50 CellSignaling, USA 
Secondary 
antibodies Host Clone Dilution Purchased from 
AF 633  Goat anti rabbit A-21070 1:100 Invitrogen, Germany 
Cy3  Goat anti rabbit 111-166-003 1:100 Dianova, Germany 
Cy3  Goat anti mouse 115-166-003 1:100 Dianova, Germany 
AF 488  Goat anti rabbit A-11008 1:100 Invitrogen, Germany 
AF 488  Goat anti mouse A-11001 1:100 Invitrogen, Germany 
AF 647  Donkey anti mouse A-31571 1:100 Invitrogen, Germany 
FITC  Goat anti mouse 115-096-003 1:100 Dianova, Germany 
FITC  Goat anti rabbit 111-096-003 1:100 Dianova, Germany 
 
2.3 Quantitative Real-Time PCR Assays 
 
Table 6: TaqMan Assays from Applied Biosystems, USA 
TaqMan® Gene Exp Assays Assays number 
TaqMan® Gene Exp Assay ARG1 Hs00968979_m1 
TaqMan® Gene Exp Assay CCL17 Hs00171074_m1 
TaqMan® Gene Exp Assay CCL18 HS00268113_m1 
TaqMan® Gene Exp Assay CD206 (MRC1) Hs00267207_m1 
TaqMan® Gene Exp Assay CD301 (CLEC10a) HS00197107_m1 
TaqMan® Gene Exp Assay cox2 (PTGS2) Hs00153133_m1 
TaqMan® Gene Exp Assay CXCL13 Hs00757930_m1 
TaqMan® Gene Exp Assay HIF1Α Hs00153153_m1 
TaqMan® Gene Exp Assay iNOS (NOS2) Hs01075529_m1 
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TaqMan® Gene Exp Assay IFNA Hs00265051_s1 
TaqMan® Gene Exp Assay IFNG Hs00989291_m1 
TaqMan® Gene Exp Assay IL1B Hs01555410_m1 
TaqMan® Gene Exp Assay IL4 Hs00929862_m1 
TaqMan® Gene Exp Assay IL4R Hs00166237_m1 
TaqMan® Gene Exp Assay IL5 Hs00174200_m1 
TaqMan® Gene Exp Assay IL6 Hs00985639_m1 
TaqMan® Gene Exp Assay IL10 Hs00961622_m1 
TaqMan® Gene Exp Assay IL12p40 Hs01011518_m1 
TaqMan® Gene Exp Assay IL13 Hs99999038_m1 
TaqMan® Gene Exp Assay IL17a Hs00174383_m1 
TaqMan® Gene Exp Assay IL21 Hs00222327_m1 
TaqMan® Gene Exp Assay IL27 Hs00377366_m1 
TaqMan® Gene Exp Assay IL27R Hs00175472_m1 
TaqMan® Gene Exp Assay MIF Hs00236988_g1 
TaqMan® Gene Exp Assay PGK1 Hs99999906_m1 
TaqMan® Gene Exp Assay P4HA1 Hs00990001_m1 
TaqMan® Gene Exp Assay RORG Hs01076122_m1 
TaqMan® Gene Exp Assay SOCS1 HS00705164_s1 
TaqMan® Gene Exp Assay STAT1 Hs01013989_m1 
TaqMan® Gene Exp Assay STAT2 Hs01013123_m1 
TaqMan® Gene Exp Assay STAT3 Hs00374280_m1 
TaqMan® Gene Exp Assay STAT6 Hs00598625_m1 
TaqMan® Gene Exp Assay TGFB1 Hs00998133_m1 
TaqMan® Gene Exp Assay TNFA Hs00174128_m1 
TaqMan® Gene Exp Assay VEGFA Hs00900055_m1 
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3 METHODS 
3.1 Patients and biopsy specimens 
Biopsied muscle tissue of all patients and patients’ muscle specimens that served as normal controls 
were analyzed retrospectively. Biopsies were taken for diagnostic reasons; no post-mortem samples 
were used. Based on specific clinical and laboratory parameters patients were assigned to certain 
entities (IIM) or diseases (DMD, BMD, fC). 
Patients with necrotizing myopathies were further divided into two subgroups (16 patients with IMNM, 
8 with nIMNM). Assignment to the immune-mediated aetiology was based on at least one of the 
following parameters: myositis-specific (MSA) or myositis-associated (MAA) autoantibodies or 
autoantibodies associated with paraneoplastic disease, and/or defined autoimmune disease. In 
contrast, the non-immune-mediated subgroup did not display any autoantibodies nor autoimmune 
disease or neoplasia. By definition, a causative toxic agent was identified in each patient suffering 
from nIMNM, whereas none of the patients with IMNM received statins prior to the muscle biopsy. 
Other conditions such as muscular dystrophy, especially dystrophinopathy or dysferlinopathy, have 
been carefully excluded in the study about NM.  
For the dermatomyositis study all patients showed clinical signs of dermatomyositis diagnosed 
according to international clinicopathological consensus criteria 115,195, e.g. skin involvement, 
dysphagia and muscle pain or weakness. Furthermore, electron microscopy showed tubular reticular 
formations. Groups were further defined depending on the age of patients: age <16 years: juvenile (15 
patients), >16 years: adult (11 patients). 
Patients with Duchenne muscular dystrophy were clearly diagnosed on the typical clinical picture and 
a muscle biopsy. For most of the patients’ gene analyses were available to determine the distinct DMD 
gene mutations (25 patients). Control groups with Becker muscular dystrophy (6 patients) and female 
carriers of the mutated DMD gene (5 patients) were analyzed and genetically proven. 
Normal controls constituted skeletal muscle biopsies derived from neurologically healthy patients of 
different age and sex, as well as without any histological or ultrastructural abnormalities, including 
absence of inflammatory infiltrates or MHC class I up-regulation, and absence of all relevant 
parameters associated with myositis (e.g. autoantibodies, signs of systemic inflammation). Normal 
control individuals were biopsied due to diffuse and rather nonspecific complaints, such as myalgia or 
fibromyalgia.  
 
All biopsies were single biopsies and the area analyzed did not significantly differ between the groups 
(measured with an Olympus BX50 microscope and the cell^D software). The entire section of each 
biopsy was analyzed, and available clinical information of patients is given in Supplemental Table 1 - 
Supplemental Table 4. Informed consent was obtained from all patients, and the Charité ethics 
committee has approved the studies (inflammatory myopathies (necrotizing myopathy and 
dermatomyositis): No. EA1/204/11, Duchenne muscular dystrophy: No. EA1/170/11). All muscle 
biopsy specimens had been cryopreserved immediately after removal at -80 °C prior to diagnostic 
work-up. 
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3.2 Histology, enzyme histochemistry, and immunohistochemistry 
All stainings were performed on 7 µm thick cryosections, produced with the ‘Microm Cryo-Star HM 
560’ (Microm Laborgeräte, Germany). The sections were stored unfixed at -20 °C or fixed at -80 °C 
until staining. Fixation was performed by incubation in acetone for 10 min. 
The 7 μm thick cryostat sections were stained with various antibodies (detailed list see below and for 
information about antibodies see section 2.2) using the iview-Ventana DAB Detection Kit with appropriate 
biotinylated secondary antibodies and diaminobenzidine (DAB)-visualization of the peroxidase reaction 
product on a Benchmark XT immunostainer in a standardized manner (both Ventana, Arizona, USA). For 
double staining of two different cellular fractions the protocol was repeated for the second primary and 
secondary antibody. Visualization with AEC (3-amino-9-ethylcarbazole, red) was used for the second 
reaction. Omission of primary antibodies in control sections resulted in absence of any cellular labelling. 
Additional stains and staining for immunofluorescence were performed in staining chambers with or 
without fixation in acetone. The sections were then blocked with the appropriate serum (1:10 in PBS) 
dependent upon the source of the secondary antibody and incubated with the afore-mentioned 
primary antibodies over-night at 4 °C or for 1h at RT. After a washing step, the secondary antibody 
was added for 1h. For double immune staining, with the purpose to show co-localisation of two cellular 
or subcellular structures, the above-mentioned protocol was performed for the first antibody and 
afterwards the same protocol was repeated with the second primary antibody and appropriate 
secondary antibody. After a final washing step, the sections were mounted and stored at 4 °C.  
Photomicrographs were taken with the Zeiss Observer.Z1 Microscope (immunofluorescence) with the 
Axiovision 4 Software (Zeiss, Germany) or with the Olympus BX50 microscope, digital camera DP25 
and the Cell^D software (Olympus, Germany). 
 
Histochemistry:  
Hematoxylin and eosin (H&E): Cell nuclei are stained in blue, while cytoplasm, connective tissue and 
other extracellular substances are colored in pink by eosin. 
Gömöri trichrome: cell nuclei are stained in red-purple, normal muscle myofibrils in green-blue, 
intermyofibrillar muscle membranes are red and interstitial collagen is stained in green. 
Elastica Verhoeff’s van Gieson (EvG): Collagen is stained in pink or deep red and other forms of 
connective tissue are colored yellow and elastic fibrils in vessels are black. 
Immunohistochemical demonstration of cells expressing:  
CD4, CD8, CD11b, CD20, CD31, CD45, CD68, CD79a, CD138, CD206, CD301, deposition of 
complement C5b9 (MAC), endothelial staining by Factor VIII (Von-Willebrand-Factor), expression of 
major histocompatibility complex (MHC) class I / II or myosin heavy chain neonatal on the 
sarcolemma, HIF-1α, Laminin-α5, vascular endothelial growth factor (VEGF-A) and presentation of 
CD56 (NCAM) and αB Crystallin.  
Antibodies, secondary antibodies, as well as other reagents used for histochemistry were stored 
according to the manufacturer at 4 °C or -20 °C. 
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3.3 Electron microscopy 
Ultrastructural analyses of all muscle specimens was performed for diagnostic after fixation in 2.5 % 
glutaraldehyde for 48 hours at 4 °C, post fixation in 1 % osmium tetroxide and embedding in araldite. 
Ultrathin sections were stained with uranyl acetate and lead citrate, after 3-5 blocks had been 
generated from each sample. Electron microscopy was performed with a Zeiss P902 electron 
microscope (Zeiss, Germany).  
 
3.4 Laser microdissection 
Laser microdissection was performed in cooperation with the ‘Neuromuskuläres Zentrum Ruhrgebiet’ 
in Bochum, Germany. The technique was applied as a method to specifically cut out regions of 
interest and perform comparative cytokine/chemokine expression level analysis via quantitative real-
time polymerase chain reaction (qPCR) after laser dissection. Cryostate slices (15 µm thick) were 
prepared on nuclease and human nucleic acid free PEN-membrane Slides from MicroDissect GmbH 
(Leica, Germany). After H&E staining with diethylpyrocarbonate (DEPC) treated, autoclaved H2O the 
slides were air-dried. 
Areas of interest within the muscle, as well as adjacent ‘normal appearing’ tissue from patients with 
dermatomyositis and healthy tissue from control patients was isolated using a laser microdissection 
system (Leica LMD6500). From each biopsy 500,000 µm2 were collected into a tube cap by focal 
melting of the membrane through the laser. Immediately after the dissection the tissue was resolved in 
500 µl trizol and stored at -80 °C until RNA isolation. 
 
3.5 Quantifications 
3.5.1 Semi-quantitative score 
We defined a semi-quantitative scale to compare patients with IMNM and nIMNM. All cases were 
graded from 0 (none) to 4 (maximum) based on different histological stainings, and characterized two 
times in a blinded manner by three independent myopathologists. Mean values from both scaling 
rounds are displayed. 
 
MHC class I expression (see Figure 5) 
0 no sarcolemmal staining 
1 > 10 % of fibres with sarcolemmal staining 
2 > 30 % of fibres with sarcolemmal staining 
3 > 60 % of fibres with sarcolemmal staining and scant sarcoplasmic staining 
4 > 90 % of fibres with sarcolemmal and strong sarcoplasmic staining 
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C5b9 complement (MAC) deposition 
0 no capillaries stained 
1 > 10 % capillaries (some/few) 
2 > 30 % of capillaries (focal) 
3 > 60 % of capillaries (large areas) 
4 > 90 % of capillaries show MAC deposition 
  
CD56+ and MHC neonatal+ fibres 
0 no fibres stained 
1 > 10 % of fibres stained 
2 > 30 % of fibres stained 
3 > 60 % of fibres stained 
4 > 90 % of fibres stained 
 
 
Figure 5: Semi-quantitative score of MHC class I immune reactivity in muscle biopsies from NM patients 
The photomicrographs illustrate the classification of cases with different degrees of MHC class I expression.  For 
details on the score see above; A = > 10 %; B = > 30 %; C = > 60 %; D = > 90 %; scale bar = 100 µm 
 
3.5.2 Cell counts 
For quantification of CD4+ or CD8+ T cells, CD20+ or CD79a+ B cells, CD138+ plasma cells, as well as 
CD68+ macrophages cell counts of 10 high power fields (HPF; one high power field is defined as 
0.16 mm2) in whole biopsy sections of each patient were performed. The average number of cells/HPF 
per case is displayed.  
 
3.5.3 Quantification of collagen VI 
For quantification of fibrosis an automatic analysis of entire whole slide images (WSI) of collagen VI 
stained muscle biopsies was performed with the Pannoramic 250 (3DHistech, Hungary). A frameless 
tessellation of WSIs at 10x magnification was applied to quantify regions of interest (ROI) piecewise 
with the ‘DMD Quantifier’ Plugin for the Cognition Master Software 196. ROIs were defined using 
manual annotation. Each slide must contain at least one positive region (pROI) to be included. Each 
pROI may contain multiple negative ROIs, which are excluded (nROI). 
For each image tile of 2,000 x 2,000 pixels a color deconvolution using one color vector triplet over the 
entire collective is applied to separate muscle fibres and connective tissue as an initial step. 
Subsequently minimum threshold is applied to the muscle layer and Otsu threshold is used for the 
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connective tissue layer for segmentation. Subsequently muscle segments are created using 
subtraction of initial connective tissue and muscle layer. Resulting segments are refined using 
morphological operations and filtered by area, form factor of contour (e.g. round, angular or elongated) 
and standard deviation of pixel intensities to remove artifacts. Finally areas of objects for both classes 
are assessed, summarized and their ratio was calculated. During processing of entire WSIs, all 
analyzed tiles together with a classified false-color image (Figure 6) and calculated results for each tile 
are saved for review and further usage.  
 
Figure 6: Quantification of fibrosis by Collagen VI staining of muscle biopsies from DMD patients 
A: Original ROI; B: processed picture of ROI; blue is defined as are of muscle cell, yellow was assessed as 
connective tissue 
 
3.5.4 Capillary density 
To determine the capillary density and number of muscle fibres in patients with DM, staining with 
laminin-α5 was manually counted with the ImageJ software on 10 HPF in whole biopsy sections of 
each patient. The average ratio of capillaries/fibres per case is displayed. 
 
Figure 7: Analysis of capillary density in DM patients 
A muscle biopsy specimen with DM was stained with an antibody directed against laminin-α5; determination of 
capillaries (red) and fibre number (blue) and both structures were counted manually. 
 
3.6 Molecular biological methods 
3.6.1 RNA isolation and quantitative real-time polymerase chain reaction (qPCR) 
Total RNA was extracted from the muscle tissue samples using the trizol/chloroform method according 
to the manufacturer’s instruction (Invitrogen, USA). Thereafter, RNA was resuspended in DEPC-
treated water and the concentration of RNA was photometrically determined with a TECAN® 
fluorescence plate reader ‘infinite M200’ (Tecan, Switzerland). Due to limited amounts of tissue after 
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isolation with laser microdissection the amount of all chemicals were reduced to ¼ of the normal 
amount.  
To eliminate contaminating DNA a DNase free Kit (Applied Biosystems, USA) was used. The RNA 
was then reversely transcribed using the High-Capacity cDNA Archive Kit (Applied Biosystems, USA) 
according to the manufacturer’s protocol by usage of 1 µg or 2 µg total RNA per sample 93. In a next 
step, the expression levels of gene-transcripts and of the endogenous control gene, phosphoglycerate 
kinase 1 (PGK1), were analyzed by qPCR using the 5’-nuclease technology on an ABI PRISM® 
7900HT Sequence Detection System and the human TaqMan® pre-developed assay reagents (both: 
Applied Biosystems, USA). The expression level of the housekeeping gene PGK1 was comparable in 
all analyzed samples and unaffected by duration of the various diseases. The assay identification 
numbers are as listed in Table 6.  
 
The qPCR reactions were prepared in a final volume of 20 µl, with the TaqMan® Fast Universal PCR 
Master Mix (Applied Biosystems, USA), containing 20 ng cDNA. All analyzes were performed in 
triplicate, the baseline was set automatically and the threshold cycle (Ct) was determined. The figures 
display either the reciprocal ∆Ct (= Ct target - Ct endogenous control) to show gene expression of the respective 
molecules compared to normal controls or the log10 of RQ-values (fold-change = 2-∆∆Ct) demonstrating 
the regulation of patient expression levels as fold-change compared to the normal controls (∆∆Ct = 
∆Ct sample - ∆Ct normal control). In these cases 0 demonstrates an expression on level of healthy controls, 1 
≙ 10-fold increase, 2 ≙ 100-fold increase, etc. Evaluation of results was performed with the Applied 
Biosystems SDS 2.3 & 2.4 software, as well as with the RQ Manager 1.2.1 (both Applied Biosystems, 
USA). 
 
3.7 Statistics 
For analyses of the semi-quantitative score of histological stains, cell counts and capillary density the 
Mann-Whitney U-test was used. Furthermore, the Kruskal-Wallis one-way analysis of variance with 
Dunns correction was applied for analyses of quantitative differences of mRNA transcripts. Data are 
presented as means with standard deviation. The level of significance was set at p < 0.05. Statistics 
were calculated with the software GraphPad Prism 5.02 (GraphPad Software, USA). 
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4 RESULTS 
4.1 Summary of patients enrolled in the project 
All groups of patients were characterized and grouped according to the underlying disease. For the 
project, different numbers of patients with necrotizing myopathy (NM), dermatomyositis (DM) or 
Duchenne muscular dystrophy (DMD) were analyzed (see below). Control groups comprised healthy 
controls (NC), patients with Becker muscular dystrophy (BMD) and female carriers of the mutated 
DMD gene (fC).  
Beside the classical symptoms of muscle disease each entity displayed characteristic features, which 
are detailed in Supplemental Table 1 - Supplemental Table 4 and discussed in the respective sections 
of each entity. Before starting analyses, all patients were evaluated for reviewing the clinical data, 
diagnostic laboratory findings and morphological characteristics. Patient biopsies not fitting the criteria 
were excluded from the study and afterwards remaining patient biopsies were histologically 
characterized and the local cytokine milieu in the muscle tissue was examined. 
 
Entity Subgroups n = 
Necrotizing myopathy (NM) immune-mediated NM (IMNM) 16 
 toxic-mediated NM (nIMNM) 8 
Dermatomyositis (DM) juvenile DM (jDM) 15 
 adult DM (aDM) 11 
Duchenne muscular dystrophy (DMD) early phase (0-3 years) 10 
 middle phase (4-8 years) 10 
 late phase (> 8 years) 5 
Healthy controls (NC)  9 
Becker muscular dystrophy (BMD)  6 
Female Carrier (fC)  5 
  
4.2 Histology of healthy control patients 
As control for all entities biopsy specimens of neurologically healthy patients of different age and sex 
were used. Muscle biopsies were performed due to nonspecific complaints of the patients to exclude 
the possibility of an inflammatory disease. The muscle biopsies were thoroughly checked for 
morphological changes and ultrastructural abnormalities. Patients with inflammatory infiltrates or MHC 
class I up-regulation, as well as other parameters associated with myositis (e.g. autoantibodies, signs 
of systemic inflammation) were excluded from the study. For future comparisons with the investigated 
diseases, the healthy, normal picture for various stainings of cellular features and resident cells is 
shown in Figure 8. 
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The biopsy from healthy muscle showed multinucleated, polygonal muscle cells (Figure 8 A). Staining 
with MHC class I (Figure 8 B) or MHC class II of capillaries (Figure 8 C) demonstrated a regular 
distribution of capillaries. Lymphocytes (CD45, Figure 8 D) and macrophages (CD68, Figure 8 E) were 
not seen in healthy patients. Regeneration as shown with MHCn staining (Figure 8 F) was not 
detected in healthy patients. Expression of dystrophin (Figure 8 G) was strong on all muscle fibres, 
while expression of utrophin was confined to capillaries and other vessels (Figure 8 H). In addition the 
sarcolemma of muscle cells were positive stained with collagen VI (Figure 8 I). 
 
Figure 8: Representative staining in muscle biopsies from healthy control patients revealed homogenous 
expression pattern and lack of immune cells 
A: H&E staining show multinucleated, polygonal muscle cells and additional staining with B: MHC class I on 
capillaries and C: MHC class II on capillaries. D: CD45+ lymphocytes and E: CD68+ macrophages are not seen in 
healthy patients. F: regeneration in healthy adult patients is not detectable. G: Staining with dystrophin shows a 
uniform staining pattern, while H: staining with Utr is confined to capillaries and other vessels. I: Collagen VI 
staining on the sarcolemma also shows a physiological distribution and staining intensity. Scale bar in A, G, I = 
200 µm and in B-F, H = 100 µm 
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4.3 Necrotizing myopathy (NM) 
4.3.1 Clinical information and general morphology of NM patients 
Patients with necrotizing myopathies can be divided into two main subgroups depending on the 
disease triggering event/agent. Patients were classified as either immune-mediated NM (IMNM, 16 
patients) or as non-immune-mediated NM (nIMNM, 8 patients) based on clinical and laboratory data. 
IMNM patients had MSA or MAA autoantibodies and/or an autoimmune disease, while the nIMNM 
patients did not have any autoantibodies or any autoimmune disease. Instead, a toxic agent was 
identified in patients suffering from nIMNM. The precise parameters are also listed in the methods 
section on page - 21 -.  
The evaluation of clinical data from all patients with NM showed no significant difference in the following 
basic parameters: the average age in both groups was similar (56.9 +/- 16.9 years in IMNM and 59.5 +/- 13.4 
years in nIMNM), as was the female/male ratio (both ~60:40) (both features Figure 9 A). However, nIMNM 
patients may develop higher CK levels as compared to those of IMNM patients (Figure 9 B and 
Supplemental Table 1). Patients with immune-mediated NM were mostly treated with steroids (12/16) and 
most of them described improvement of symptoms (e.g. reduction of muscle pain or weakness) during the 
following period of observation. Only in two cases this therapy had no beneficial effect. In contrast, in 
nIMNM the triggering agent (e.g. medication) was removed and mostly no further data about development 
of the disease were available. (Supplemental Table 1) 
 
Figure 9: Age, sex and CK level are comparable in both subgroups of patients with NM 
A: Age of patients with IMNM and nIMNM in comparison to NC is shown; furthermore, the number of female and 
male patients is displayed by colored squares. B: Fold-increase of CK values in both subgroups of NM. The 
nIMNM patients develop higher CK levels than IMNM patients. Statistical analysis in A and B were performed with 
Mann-Whitney U-test, p < 0.05 was considered significant. 
 
The general picture of the disease shown by routine histochemical staining with H&E staining (Figure 
10 A, B) and Gömöri trichrome (Figure 10 C, D) was basically comparable in both subgroups, with 
regard to myophagocytosis and myofibre necrosis. Both elements were detectable, independently 
from disease aetiology.  
To exclude features of other diseases the biopsies were analyzed for the presence of perifascicular 
pattern of atrophic fibres and for a gradient of increasing capillary density towards the center of the 
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fascicles, as it is found in dermatomyositis patients, but neither one was a feature in the IMNM muscle 
specimens. Electron microscopic investigation further ruled out the presence of undulating tubules in 
endothelial cells, which is another ultrastructural feature of DM (Figure 10 E, F). 93 
 
Figure 10: Representative illustration of morphological characteristics in both subgroups of NM patients 
A, B: H&E staining and C, D: Gömöri trichrome stainings illustrate the general picture of disease and show 
myophagocytosis and necrosis of muscle fibres; E, F: representative pictures of electron microscopy show no 
undulating tubules in endothelial cells of capillaries in either IMNM nor nIMNM patients. * = necrotic muscle fibre; 
scale bar = 100 µm, EM magnification x30,000 
 
4.3.2 Number and distribution of immunological cells in inflammatory infiltrates 
differs between IMNM and nIMNM patients 
To differentiate the subtypes of NM and to characterize the inflammatory infiltrate in more detail, 
additional immunohistochemistry and ultrastructural analyses were performed.  
It has been stated by many researchers that IMNM, especially anti-SRP-associated NM, is 
characterized by a ‘poor cellular infiltrate’ 91,92. Therefore, not only the presence but also the specific 
distribution of interstitial immune cells were investigated. Using immunohistochemistry it was shown 
that the inflammatory infiltrate in IMNM muscle tissue (Figure 11 A), but not in nIMNM muscle tissue 
(Figure 11 B), consists of a substantial amount of macrophages (Figure 11 A, B). Histologically these 
macrophages were either iNOS+ (Figure 11 C, D) or CD206+ (Figure 11 E, F).  The analysis of mRNA 
expression levels showed expression of NOS2 (iNOS) in both, IMNM and nIMNM, of the same level as 
healthy controls (Figure 11 H), while CD206 (MRC1) expression was significantly elevated as 
compared to NC (Figure 11 H). In addition, the quantification of immune cells using cell counts on 
serial sections in the biopsy samples showed that the CD68+ macrophages quantitatively constituted 
the dominant mononuclear cellular infiltrate in IMNM (Figure 11 G), independent of myophagocytosis. 
IMNM muscle tissue had huge numbers of CD68+ macrophages in the endomysium and perimysium, 
while these cells were significantly fewer and exclusively confined to necrotic fibres in patients with 
nIMNM (Figure 11 G).  
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Figure 11: Numbers of macrophages in cellular infiltrates of patients with IMNM are significantly higher 
when compared to nIMNM 
A, B: Histologically stained CD68+ cells in NM and C, D: staining of biopsy specimens for iNOS. E, F: as well as 
with CD206. G: Cell count of CD68+ cells in both subgroups of NM. IMNM patients have higher numbers of 
macrophages, while the number of cells in nIMNM is low. H: qPCR analysis showed expression of the pro-
inflammatory cytokine iNOS (NOS2) and the AAM molecule CD206 (MRC1) when compared to that of NC (1 ≙ 
10-fold increase). Statistical analysis in G was performed with Mann-Whitney U-test and in H with Kruskal-Wallis 
one-way ANOVA with Dunn´s multiple comparison test, p < 0.05 was considered significant (* ≙ p < 0.05, ** ≙ p < 
0.01). Arrows indicate immunoreactive cells of the respective subtype; A-D: * = necrotic muscle fibre; scale bar = 
100 µm 
 
 
Using staining for CD4 and CD8, the T cells within the muscle biopsies were analyzed. As shown in 
Figure 12 the inflammatory infiltrate in IMNM muscle tissue comprised CD4+ (Figure 12 A) and CD8+ T 
cells (Figure 12 C) and in some cases, the T cells were also identified in a perivascular location. In 
contrast, nIMNM biopsies displayed only scant T cells in the endomysium and in proximity to fibre 
necrosis and myophagocytosis (Figure 12 B, D). As already seen in histological sections, the 
quantification of T cells showed a considerable amount of T cells in IMNM, while numbers of T cells in 
nIMNM were low (Figure 12 E). In comparison to CD68+ macrophages, the numbers of T cells in 
IMNM is lower (Ø 30 macrophages vs. Ø 18 T cells, Figure 11 E, Figure 12 E). 
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Figure 12: Numbers and distribution of T cells in cellular infiltrates differ between IMNM and nIMNM 
patients 
A, B: CD4+ cells stained in immunohistochemistry in NM patients and C, D: staining with an antibody against CD8. 
E: Cell count of CD4+ and CD8+ cells in both subgroups of NM. IMNM patients have higher numbers of T cells, 
while the number of cells in nIMNM is low. Statistical analysis in E was performed with Mann-Whitney U-test, p < 
0.05 was considered significant (*** ≙ p < 0.001), Arrows indicate immunoreactive cells of the respective subtype; 
* = necrotic muscle fibre; scale bar = 100 µm 
 
In addition to macrophages and T cells, the role of B cells in inflammatory myopathies was of interest, 
since their contribution in IIMs is still unclear. Nevertheless, in a few severely ill patients with anti-SRP-
autoantibodies, B cell depletion therapy with Rituximab has been used with only little effect 89,197. 
Therefore, the participation of B cells was assessed in more depth and molecular molecules for B cell 
recruitment into the skeletal muscle were analyzed.  
Three out of the 16 muscle biopsy specimens showed few CD79a+ B cells and in some cases CD138+ 
plasma cells were detected in the endomysium (Figure 13 A, C), while the nIMNM biopsies did not 
display any substantial numbers of B cells or plasma cells (Figure 13 B, C). The molecular analysis of 
the B cell chemoattractant CXCL13 198,199 in muscle specimens further revealed significantly higher 
expression of this chemokine in IMNM as compared to nIMNM, as well as in comparison to NCs 
(Figure 13 D). Accordingly, patients with increased expression of CXCL13 were also those with 
histologically proven presence of B cells. Since CXCL13 expression is also seen in muscle tissue of 
IMNM biopsies without histologically proven B cells, the recruitment in these patients might just have 
started. It was further shown, that beside follicular dendritic cells, also macrophages are able to 
produce CXCL13 200, again demonstrating their involvement in immune cell recruitment. In addition, 
some of the patients with B cells or high expression of CXCL13 were positively tested for myositis-
antibodies (color coded in Figure 13 C, D, anti-Jo1- or anti-SRP-autoantibodies). This might hint at an 
association between antibodies and e.g. prognosis of disease or responsiveness to treatment, since 
correlations between antibodies and clinical findings have been reported in various studies 3,110,201. 
However, the number of B cells in IMNM muscle tissue overall was very low rendering the importance 
of these cells for therapeutic approaches questionable. 
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Figure 13: Histological and molecular analyses of B cells in both subgroups of NM   
A, B: Immunohistochemical staining with CD79a in NM muscle tissue. C: Cell counts revealed single cases with B 
cells or plasma cells in IMNM patients. D: The expression of the B cell chemoattractant CXCL13 is illustrated in NM 
as compared to NC (1 ≙ 10-fold increase, 2 ≙ 100-fold increase). Some patients with B cell infiltration also showed 
increased expression levels of CXCL13 (marked by colored squares: orange ≙ anti-Jo1 Ab; green ≙ anti-SRP Ab). 
Statistical analysis in D with Kruskal-Wallis one-way ANOVA and Dunn´s multiple comparison test, p < 0.05 was 
considered significant (** ≙ p < 0.01). Arrows indicate immunoreactivety of the CD79a+ cells; scale bar = 100 µm 
 
4.3.3 Additional histological features allow differentiation of IMNM and nIMNM patients 
Next I investigated the distribution of  MHC class I molecule expression by immunohistochemistry, because 
conflicting results were published concerning ‘the intensity of its expression and the expression pattern’ 
97,98,111,202. Hengstman et. al. described a case series, where MHC staining in muscle biopsies was 
completely absent 98, while Christopher-Stine et. al. showed sarcolemmal MHC class I staining on 50 % of 
the evaluated patients with HMGCoA antibodies 97. In the present study, IMNM patients in general 
exhibited a prominent expression of MHC molecules on a large number of non-necrotic muscle fibres 
(Figure 14 A). The expression was thereby diffusely distributed and particularly strong in biopsies derived 
from patients with anti-SRP or anti-synthetase antibodies and in paraneoplastic NMs. The investigations of 
muscle biopsies from nIMNM patients revealed MHC class I expression confined only to the sarcoplasm of 
necrotic fibres, as well as a scant sarcolemmal staining on few adjacent fibres (Figure 14 B). As expected 
no significant or diffuse up-regulation of MHC molecules on non-necrotic fibres was found in nIMNM 
biopsies (Figure 14 B) and these myofibres are therefore not targeted by a potential T cell response. 
Since necrotic fibres are a hallmark in patients with NM, and the membrane attack complex is involved in 
cell decay, the complement deposition of the membrane attack complex (MAC; C5b9) was studied. As 
demonstrated by histology complement deposition was particularly prominent especially on capillaries in 
IMNM biopsies (Figure 14 B), again especially in patients where anti-SRP or anti-synthetase 
autoantibodies were found. The same was true in biopsies derived from patients with paraneoplastic 
aetiology. Semi-quantitative scores of the stainings further showed a significantly stronger expression of 
MHC class I and C5b9 in IMNM as compared to nIMNM (Figure 14 E). The complement deposition on 
capillaries in the nIMNM group was insignificant or completely absent (Figure 14 D, E). 
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Figure 14: Analyses of sarcolemmal MHC class I expression and complement deposition showed 
differences between the NM subgroups 
A, B: Histological staining of MHC class I and C, D double immunofluorescence of complement C5b9 (red) and 
factor VIII (green) in NM patients. E: Quantification of histology showed the amount of MHC class I expression, as 
well as of C5b9 deposition. For definition of scale see methods: 0 = min; 4 = max. Statistical analysis in E was 
performed with Mann-Whitney-U-test, p value < 0.05 was considered significant (*** ≙ p < 0.001); * = necrotic 
muscle fibres, scale bar = 100 µm 
 
In addition to the mentioned complement deposition on capillaries, which was also previously described 1, a 
further interesting and discriminating feature of severe IMNM cases was the decoration of the sarcolemma 
of non-necrotic fibres by MAC (Figure 15 A). This feature was consistently absent in biopsies from patients 
with nIMNM (Figure 15 B). With the characteristic sarcoplasmic labelling with αB-crystallin, some of these 
fibres were identified as so called X fibres 203 (Figure 15 C), which appeared otherwise normal by trichrome 
or H&E stain (Figure 10 A, C). These findings may indicate that the X fibres are committed to be attacked 
by the immune system. X fibres were consistently absent in nIMNM specimens (Figure 15 D). 
 
Figure 15: Deposition of complement and labelling of X fibres is prominent in IMNM patients 
A: Sarcolemmal decoration of muscle fibres with complement in IMNM and B: staining of nIMNM patients. C: In 
IMNM αB-crystallin staining was seen, D: while no staining was seen in nIMNM. scale bar = 50 µm 
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Considering the different aetiologic backgrounds I hypothesized that regenerating processes would 
possibly differ between muscle biopsy specimens from patients with an immune background, 
compared to patients with toxic aetiology. To identify regenerating fibres I used antibodies against 
neural cell adhesion molecules (NCAM; CD56), which are involved in cell-cell adhesion, and myosin 
heavy chain neonatal (MHCn), a molecule expressed by newly formed myotubes. In IMNM the number 
of regenerating fibres was significantly more pronounced as indicated by the presence of numerous 
NCAM+ (CD56) or MHCn+ muscle fibres (Figure 16 A, C), whereas these molecules were less 
frequently detected in biopsies from patients with nIMNM (Figure 16 B, D). Semi-quantitative score of 
the histology revealed that regeneration in IMNM is enhanced as compared to nIMNM, but not on a 
significant level (Figure 16 E). The increased regeneration rates in IMNM argue for a high turnover of 
necrotic and inflamed muscle fibres and potential restoration of healthy tissue. This meets the 
observation that patients might be cured after therapy wherby no muscle symptoms remain. 
 
Figure 16: Regeneration processes are elevated in IMNM patients when compared to nIMNM 
A, B: Illustration of regeneration in NM patients by staining with CD56 and C, D: MHCneonatal. E: Semi-quantitative 
score of immunohistochmical stainings showed increased regeneration in IMNM as compared to nIMNM, however 
without statistical significance. Statistical analysis in E were performed with Mann-Whitney U-test, p < 0.05 was 
considered significant; arrows indicate immunoreactive cells of the respective subtype; scale bar = 100 µm  
 
4.3.4 Differential expression of cytokines/chemokines revealed differences between 
IMNM and nIMNM patients 
Based on the above mentioned quantitative studies concerning the inflammatory mononuclear 
infiltrates in NM biopsy specimens, I hypothesized that the immune pathogenesis of the disease might 
be essentially regulated by macrophages and T cells. Therefore, I analyzed key molecules of the pro- 
and anti-inflammatory immune milieu by qPCR, as well as mediators for classical and alternative 
activated phenotypes of macrophage polarization 18,26,28,32.  
As illustrated in Figure 17 the cytokine expression level of muscle tissue derived from IMNM patients was 
characterized by a significant up-regulation of the pro-inflammatory master cytokine IFNG, as well as the 
cytokines TNFA, IL12p40 and the transcription factor STAT1 28,204 as compared to NCs (Figure 17 A, B). In 
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nIMNM samples, the respective cytokines were expressed at lower levels when compared to those in 
IMNM (Figure 17 A, B), indicating a lower pro-inflammatory response in patients with toxic-mediated 
aetiologies. Furthermore, the effector molecule cox2 (PTGS) was not differentially regulated in either group, 
which may mirror comparable up-regulation in the muscle tissue (Figure 17 A) and in addition they were 
only insignificantly elevated when compared to NCs. Expression of the T cell stimulating cytokine IL12p40 
was increased in IMNM as compared to nIMNM and NCs ( Figure 17 B). 
Gene expression measurements of the master cytokines of TH2 immunity, IL4 and IL13, revealed no 
significant expression (Figure 17 D). In line with this finding, the gene expression of the common IL-4 
receptor alpha (IL4RA; CD124), which mediates IL-4 and IL-13 signaling, as well as expression of the 
macrophage mannose receptor (MRC1; CD206) were expressed at similar levels in both groups (Figure 17 
C). Both were significantly elevated when compared to NCs in IMNM and in case of CD206 also in nIMNM. 
In addition, TGFB and CCL18 were elevated in IMNM patients, in case of CCL18 on a significant level 
(Figure 17 C). The expression of these molecules demonstrates an involvement of anti-inflammatory 
reactions in NM patients in addition to the up-regulation of pro-inflammatory cytokines. 
 
Figure 17: Expression of pro-inflammatory cytokines NM patients 
A: Expression of pro-inflammatory mediators in IMNM and nIMNM as compared to NC (1 ≙ 10-fold increase, 2 ≙ 
100-fold increase). B: The pro-inflammatory molecule IL12 is not expressed in NM; nor in NC. C: Expression of 
anti-inflammatory molecules is not differentially regulated in both groups and D: anti-inflammatory cytokines are 
not expressed. Statistical analysis was performed with Kruskal-Wallis one-way ANOVA with Dunn´s multiple 
comparison test. It was not possible to perform statistics for the expression of IL12p40, IL4 and IL13, because the 
respective cytokines were not expressed in NC; p value < 0.05 was considered significant (* ≙ p < 0.05, ** ≙ p < 
0.01). 
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4.3.5 Recapitulation 
Patients suffering from necrotizing myopathy can be clearly divided into two distinct subgroups 
depending on laboratory and histological parameters. The clinical background and medical history 
gave already hints for a correct classification into immune- or non-immune NM, which illustrates the 
importance of a comprehensive clinical evaluation of the patient history.  
Moreover, histological analyses were further identified as tools to clarify the nature of the respective 
disease subtype. The immune reaction in patients with IMNM is defined by a TH1-like, pro-
inflammatory milieu, with up-regulation of IFNG and TNFA. Using quantification it was clearly 
demonstrated that macrophages were the predominant cell population and spread throughout the 
muscle. In addition, considerable amounts of T cells were found in the inflammatory infiltrates of IMNM 
patients. Furthermore, a clear expression of MHC class I molecules and C5b9 deposition were 
detected in IMNM, while none of these features were detected in NMs with an toxic aetiology adding 
additional features to distinguish the different subtypes of NM.  
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4.4 Dermatomyositis (DM) 
4.4.1 Clinical information and general morphology of DM patients 
Patients with dermatomyositis were analyzed with respect to various clinical data, summarized in 
Supplemental Table 2. One of the most important diagnostic characteristics was the presence of 
undulating tubules in endothelial cells of capillaries of skeletal muscle, which were found by electron 
microscopy (Figure 19 E, F). For evaluation the group of DM patients was split into juvenile patients 
(jDM, 15 patients, age of onset < 16 years) and adult patients (aDM, 11 patients). 
In the jDM patients the gender distribution between girls and boys was 50:50, whereas in the aDM 
more women were affected than men (70:30) (Figure 18 A). The mean age in juvenile patients was 
7.0 +/- 4.3 years, whereas the adult patients were 61.0 +/- 14.7 years old (Figure 18 A). These age-
frames fit perfectly with previously published data 116,117,131. 
Therapeutic strategies were different from patient to patient, but glucocorticoid treatment was the 
most common therapy, with methotrexate or azathioprine as a long-term immune modulator. The 
success of therapy also varied strongly between patients. Overall, jDM patients showed a better 
response to steroid treatment. Most of the patients experienced partial or complete remission of 
symptoms (11/15 remission and 4/15 remitting-relapsing). In aDM patients, fewer individuals 
showed improvement/partial improvement (5/11) and in two patients no effect of the therapy was 
seen. For the remaining patient’s no further information was available about long-term development 
of the disease. 
 
Figure 18: Age, sex and CK levels in jDM and aDM patients 
A: Age of patients with jDM and aDM in comparison to that of NC is shown; furthermore, the number of female 
and male patients is displayed by colored squares. B: Fold-increase of CK values in both groups of DM. Statistical 
analysis in A, B were performed with Mann-Whitney U-test, p < 0.05 was considered significant (*≙ p < 0.005, **** 
≙ p < 0.001). 
 
 
RESULTS 
- 39 - 
Histological stainings with H&E or Gömöri trichrome revealed the general picture of the disease with 
clear inflammatory infiltrates, especially in perimysial areas. Biopsies from jDM and aDM patients 
displayed the same morphological picture of DM with widened perifascicular areas, inflammatory 
infiltrates and muscle fibre atrophy predominantly in the perimysial area (Figure 19 A-D). These 
effects were also described before 205 confirming the correct classification of this patient cohort.  
 
Figure 19: Representative staining of morphological characteristics in jDM and aDM patients 
A, B: The general overview for aDM and jDM patients is displayed with H&E staining and C, D: Gömöri trichrome. 
A typical perifascicular atrophy pattern is seen. E, F: Another hallmark of DM is the presence of undulating 
tubuloreticular structures in endothelial cells (indicated by arrows), which are shown by electron microscopy. 
Scale bar = 200 µm, EM magnification x30,000 
 
4.4.2 Composition of infiltrates is similar in both subgroups of DM patients 
In the biopsy specimens of patients with DM CD4+ and CD8+ T cells were detected in the 
endomysium, as well as in the perimysium of all patients (Figure 20 A-D). In contrast to T cells, only 
few CD79a+ B cells were observed in both groups (Figure 20 E, F). Quantification of lymphocytes 
revealed that there was no significant difference in the number of CD4+ / CD8+ T cells (Figure 20 G) 
or B cells (Figure 20 H) in both subgroups. Cell counts of CD138+ plasma cells showed that there 
were only low numbers in both groups; however some aDM patients exhibited high numbers of 
plasma cells increasing the mean value for the whole group to a significant level between aDM and 
jDM (Figure 20 H). 
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Figure 20: Composition of the inflammatory infiltrate in DM patients is similar 
A, B: CD4+ T cells are found perifascicular, as well as C, D: CD8+ T cells. E, F: CD79a+ B cells are scant and 
mostly not detected in jDM; nor aDM patients. G: Quantification of T cells in DM patients and H: quantification of B 
cells in jDM and aDM. Statistial analysis was performed with Mann-Whitney U-test, p < 0.05 was considered 
significant. Arrows indicate representative immunoreactive cells of the respective subtype; scale bar = 200 µm 
 
 
The most prevalent population of inflammatory cells throughout the biopsies of DM patients were 
CD68+ macrophages with a large proportion of CD206 positivity and with a clear accumulation in the 
perifascicular region (Figure 21 A, B). In addition, macrophages were identified in or around necrotic 
fibres (Figure 21 A, B). Macrophages were either iNOS+ (Figure 21 C, D) or CD206+, while the 
histological staining was more intense for CD206 staining (Figure 21 E, F). Overall, there was no 
significant difference in the number of immune cells of jDM as compared to aDM patients, as shown by 
counting of CD68+ cells (Figure 21 G). On the molecular level, jDM patients showed a trend for up-
regulation of the cytokine cox2 (PTGS), while expression of these molecules in aDM was on the level 
of NCs (Figure 21 H). In contrast to that, the expression of CD206 was significantly elevated in aDM 
patients when compared to jDM, as well as to that of NC (Figure 21 H). This speaks for different 
prevalent milieus and therefore activation pathways in jDM in contrast to that of aDM. 
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Figure 21: Involvement of CD68+ macrophages in cellular infiltrates of patients with DM 
A, B: CD68+ cells in DM patients and C, D: staining of biopsy specimens with iNOS and E, F: CD206. G: 
Quantification of macrophages in patients with DM showed no difference between the groups. H: qPCR analysis 
of DM patients showed expression of the pro-inflammatory cytokine cox2 (PTGS) and the molecule for AAMs 
CD206 (MRC1) when compared to NC (1 ≙ 10-fold increase). Statistical analysis in G were performed with Mann-
Whitney U-test and in H with Kruskal-Wallis one-way ANOVA with Dunn´s multiple comparison test, p < 0.05 was 
considered significant (* ≙ p < 0.05, ** ≙ p < 0.01). Arrows indicate immunoreactive cells of the respective 
subtype; scale bar = 200 µm 
 
4.4.3 Perifascicular atrophy and regenerative processes are prominent in jDM patients 
In addition to the inflammatory infiltrates, a difference in the histological staining pattern of various 
proteins in jDM as compared to aDM was seen. A typical perifascicular pattern was identified by 
various stainings in DM patients, and exemplarily shown here by MHC class I and MHC class II 
expression (Figure 22 C, D). The up-regulation of MHC class I and MHC class II might not only be a 
reaction to the inflammatory infiltrates, but rather a separate pathological event in DM 206. In terms of 
expression intensity of both MHCs no differences were observed between jDM and aDM patients.  
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Figure 22: Expression of MHC class I and MHC class II is strong in patients with DM 
A: Expression of MHC class I was strong on muscle fibres in jDM, as well as B: in aDM. The same picture is seen 
in C, D: expression of MHC class II. Scale bar = 200 µm 
 
Furthermore, the perifascicular pattern demonstrates atrophy and regeneration, which was more 
prominent in jDM patients (Figure 23). Expression of CD56 (Figure 23 A) was high in jDM and also 
expression of MHCn (Figure 23 C) was frequently detected. In contrast to the pronounced 
regeneration in jDM, the up-regulation of proteins in aDM patients was less strong (Figure 23 B, D). 
Regenerative processes seemed therefore less involved in the pathogenesis of the disease in adults 
when compared to those in juvenile patients. 
 
Figure 23: Regenerative processes are increased in patients with jDM 
A: Regeneration is detected in jDM patients by staining of CD56+ cells and C: MHCn+ fibres. B, D: Expression of 
the molecules CD56 and MHCn is weaker in aDM. Arrows indicate immunoreactive cells of the respective 
subtype; scale bar = 200 µm 
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4.4.4 Hypoxia and prominent capillary loss is more pronounced in jDM as compared 
to aDM patients 
It is known that hypoxic events occur in DM patients, but its impact on pathogenesis is unclear, as well as 
its different contribution in the juvenile or adult form of the disease. Therefore hypoxic key molecules were 
analyzed by protein expression and on molecular level in both sub-entities. Hypoxic reactions 
demonstrated by expression levels of the hypoxia-inducible factor 1α (HIF1α, Figure 24 A, B) or induction 
of the vascular endothelial growth factor (VEGF, Figure 24 C, D) was observed in DM patients. Regulations 
of hypoxia might be due to up-regulated expression of HIF-1α and its target genes. Hypoxia was also 
mostly found in the perifascicular, atrophic areas of the muscle in jDM (Figure 24 A). In contrast to these 
results, none of the aDM patients showed extensive positive staining for HIF-1α (Figure 24 B). In addition, 
VEGFA expression was strong in jDM patients (Figure 24 C) and less intense in aDM (Figure 24 D).  
 
Figure 24: Signs of hypoxia are prominent in jDM patients, but not in aDM patients 
A, B: Staining with HIF-1α is found with a perifascicular distribution in jDM, while aDM patients show only low 
immunoreactivity. C, D: The same picture is found for the vascular endothelial growth factor (VEGFA). Arrows 
indicate representative immunoreactive fibres of the respective subtype. Scale bar = 200 µm 
 
Another distinct feature of patients with DM is a loss of capillaries, mostly in the centre of the fascicle, 
which leads to decreased oxygen supply and enhanced effects of hypoxia 145. However, until now no 
comparative studies has been performed between jDM and aDM, to determine differences or similarities 
in the amount of capillary loss. Therefore, density and distribution of capillaries in biopsies with DM were 
determined. As shown in Figure 25 most patients with DM were affected by capillary loss (Figure 25 A, B, 
E). Nevertheless counting of single capillaries and muscle fibres demonstrated that jDM patients are more 
strongly affected by capillary loss than aDM patients. As visualised, the ratio between capillaries and 
fibres was significantly decreased in jDM in comparison to aDM and NC (Figure 25 E), while this reduction 
was only seen in some aDM patients (Figure 24 E). Another striking phenomenon was the spatial 
proximity of macrophages to the capillaries and bigger vessels. This close association of macrophages 
and vessels was seen in both, jDM and aDM (Figure 25 C, D), indicating a close interaction between 
activated macrophages and endothelial cells. 
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Figure 25: Loss of capillaries is significant in jDM, but not in aDM patients  
A, B: Staining of capillaries in DM patients; C, D: Double staining of CD206+ macrophages (red, black arrows) 
with Lam-α5 for capillaries (brown, grey arrows). E: Counting of muscle fibres and capillaries demonstrated a 
significantly reduced capillary/fibre ratio in jDM patients compared to aDM and NC; statistical analysis in E with 
nonparametric t-test and Mann-Whitney post-test, p value < 0.05 was considered significant; scale bar = 200 µm 
 
4.4.5 Pro- and anti-inflammatory cytokine expression is found in subgroups of DM  
For investigation of the underlying cytokine milieu, RNA from whole tissue was used for analysis by qPCR. 
Pro- and anti-inflammatory cytokines were not expressed at different levels between the groups and were 
not significantly regulated when compared to NC (Figure 26 A-D). However, some pro-inflammatory 
molecules, such as IL6, IL1B and TNFA, seemed to be more highly expressed in jDM than in aDM, but 
without statistical significance (Figure 26 A). In contrast, IL-17-asscociated molecules were not expressed 
in either group of DM, indicating that IL-17-associated immune responses were not prevalent in DM 
patients (Figure 26 B). The same was true for anti-inflammatory molecules, such as IL4, IL13 and IL5 
(Figure 26 B). 
 
Figure 26: Cytokine profile in jDM and aDM patients is similar to those of NCs 
A: Pro-inflammatory cytokines and molecules of classically activated macrophages in DM patients. Regulation is 
not significantly changed when compared to NC (1 ≙ 10-fold increase, 2 ≙ 100-fold increase). B: Pro- and anti-
inflammatory molecules are not differentially expressed in jDM or aDM patients. Statistical analysis was 
performed with Kruskal-Wallis one-way ANOVA with Dunn´s multiple comparison test. It was not possible to 
perform statistics for the expression of IFNA, IL12p40, IL21, IL17A, IL4, IL13 and IL5, because the respective 
cytokines were not expressed in NC, p < 0.05 was considered significant. 
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4.4.6 Enhanced hypoxia in DM patients is predominantly located in perifascicular areas 
In addition to the pro- and anti-inflammatory pathways, molecules known to be involved in hypoxic 
reactions were investigated. Factors, activated under hypoxic conditions like VEGFA, HIF1A and MIF, 
were increased when compared to NC (Figure 27 A). However, only gene expression of TGFB and 
MIF showed a significant elevation. It has been shown, that TGFβ activity up-regulates HIF-1α, which 
in turn up-regulates various proteins as well as transcription factors 207. Therefore the up-regulation of 
TGFβ fits with these data.  
To further dissect the reactions within the muscle fibres hypoxic perimysial area as well as ‘normal 
appearing’ adjacent muscle fibres of the central region of fascicles were isolated via laser 
microdissection. With this technique the investigation of hypoxic reaction without a potential masking 
effect of the surrounding tissue was possible. Perimysial regions are important in DM, since 
inflammatory infiltrates are located in these areas and atrophy is found at the rim of the fascicles. The 
center of the fascicles appeared normal in histological stainings and differences in gene expression 
levels could give insights into regions of pathological reactions in DM. The latter is interesting, since 
widened perimysium is a hallmark in DM, while it is not seen in other myopathies. As expected, 
molecular expression of hypoxic molecules was elevated in perimysial areas, whereas expression was 
not detectable in non-atrophic, centro-fascicular tissue of the same patient (Figure 27 B). Especially 
HIF1A, MIF and VEGFA were increased, while expression of TGFB1 was not detected. In adjacent 
‘normal appearing tissue’ the DM patients did not show any expression and neither was the case in 
NC (Figure 27 B). 
 
Figure 27: Gene expression levels are elevated in whole tissue and LCM-isolated tissue from DM patients 
A: Gene expression levels for molecules associated with hypoxia from whole muscle tissue were analyzed. B: 
Normal appearing tissue and the perifasicular area of patients was LCM isolated and compared to LCM isolated 
tissue from NC. Hypoxia-associated molecules were investigated. Statistical analysis in A were performed with 
Kruskal-Wallis one-way ANOVA with Dunn´s multiple comparison test, p < 0.05 was considered significant (* ≙ p 
< 0.05, ** ≙ p < 0.01), while due to the low number of samples after LCM isolation it was not possible to perform 
statistical analysis. 
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4.4.7 Recapitulation 
Combining analyses of the clinical and morphological picture I demonstrated that the patient cohort 
showed previously published features of DM. Besides infiltrates, containing T cells, B cells and 
macrophages an up-regulation of MHC class I and MHC class II was seen in all patients independent 
of their age. However, comparative analyses between jDM and aDM had not been performed before, 
and these analyses demonstrated that the composition of inflammatory infiltrates in both sub-entities 
was comparable. In addition, the typical atrophic, perifascicular pattern was identified, as well as 
effects of hypoxia. Both features were more pronounced in jDM as compared to aDM patients. In 
addition, these effects were confirmed by qPCR analyses, where factors associated with hypoxia were 
found up-regulated in jDM and aDM as compared to NC. Through laser microdissection I further 
demonstrated, that the effects of hypoxia were based on reactions located in the perifascicular area, 
while the adjacent tissue of the same patients showed no hypoxia-associated regulation. This may be 
the key for understanding of pathological mechanisms in DM. In line with these findings, the loss of 
capillaries in DM muscle tissue was determined. The quantification of capillaries per fibre showed, that 
capillary loss was also more prominent in jDM patients and co-staining of macrophages with capillaries 
further demonstrated a close spatial proximity between these cells. 
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4.5 Duchenne muscular dystrophy (DMD) 
4.5.1 Clinical information in patients with DMD and basic histology of the control 
groups (BMD, fC) 
For analysis of patients with Duchenne muscular dystrophy (25 patients) biopsy samples were 
analyzed depending on the age of patients at time of biopsy and other available information, such as 
mutation in the DMD gene, development of symptoms and therapy. All information is given in 
Supplemental Table 3.  
Affected boys were mostly asymptomatic at the age of 0-3 years (early phase), but proximal muscle 
weakness and inflammation were developing in the following years (4-8 years, middle phase). The late 
phase of the disease (older than 8 years) was marked by increasing weakness, fibrosis and loss of 
ambulation. Further problems such as heart failure, breathing problems and scoliosis were emerging. 
Beside these signs the CK value was often extremely elevated and can be increased up to 200-fold 
208, as also shown in Figure 28 A for available information. At time of biopsy all of these typical 
developments were found in the examined patients (Supplemental Table 3). Gene mutations 
comprised mostly gene deletions, but in addition duplications and point mutations were detected 
(Figure 28 C). 
 
As control groups, besides NC, patients with Becker muscular dystrophy (BMD, 6 patients) were 
analyzed additionally. The male patients suffering from BMD were overall less strongly affected than 
DMD patients, but walking problems or cardiomyopathy may be found. Female carriers of the mutated 
DMD gene (fC, 5 patients) were also examined, where carriers are often asymptomatic. Information for 
these groups is given in Supplemental Table 3. 
 
 
Figure 28: Clinical information of patients with DMD, BMD and fC 
A: Age of patients at time of biopsy with DMD in comparison to control groups (BMD, fC, NC) is shown; 
furthermore, the number of female and male patients is displayed by colored squares. B: Fold-increase of 
available CK values in patients with DMD. C: Summary of known gene mutations in patients with DMD. Statistical 
analysis was performed with Mann-Whitney U-test, p < 0.05 was considered significant (* ≙ p < 0.05). 
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Expression of dystrophin was absent in patients with DMD (Figure 29 A), while in fC the expression of 
dystrophin was only diminished in a mosaic pattern, as seen in Figure 29 B. For patients with BMD a 
similar picture was seen, expression of dystrophin was reduced, but not completely absent (Figure 29 
C). In contrast, expression of utrophin was up-regulated in DMD and BMD (Figure 29 D, F), while fC 
had lower sarcolemmal expression of utrophin in general (Figure 29 E). 
 
Figure 29: Expression pattern of dystrophin and utrophin differs between DMD patients and control groups 
A: Expression of dystophin in DMD patients is completely absent, while expression in B: fC and C: BMD is still 
detectable. D: Expression of utrophin is strong in DMD, while E: fC show lower expression and F: BMD patients 
harbor some increased expression. Scale bar = 100 µm 
 
4.5.2 Morphology is characterized by cellular infiltrates, inflammation and fibrosis 
The morphological picture in DMD patients is quite variable, depending on the age of the patient and 
therefore the stage of disease. Variation of the mutation leads to different levels of dystrophin 
expression and influences not only the morphological picture but also progression of the disease. The 
starting point of treatment with corticosteroids also differs between patients, additionally influencing 
the development of disease. Nevertheless, to get an overview about the morphology patients were 
grouped according to current stage of disease to display development of the disease over time (Figure 
30 A-C). The morphological picture was also depicted for BMD and fC (Figure 30 D, E). As seen in the 
H&E stainings (Figure 30 A-E) and Gömöri trichrome (Figure 30 F-J) increasing muscle pathology was 
observed with increasing age of patients and especially the first 8 years were minted by inflammation 
and cellular cell infiltration (Figure 30 A-B & F, G). Starting around the time when DMD patients have 
to rely on wheelchairs (> 10 years), the amount of inflammation was reduced, while development of 
fibrosis and replacement of fibres by fatty tissue dominated the morphological picture (Figure 30 C). 
Development of fibrosis was nicely visualized by EvG staining, where collagen is stained in pink and 
skeletal muscle is stained in dark yellow. In the control groups, the same features were found, 
however with a different degree of severity and Figure 30 demonstrated inflammatory infiltrates in 
BMD and fC, while fibrosis was weaker in BMD patients as compared to DMD (Figure 30 O), but may 
be substantial in fC (Figure 30 N). 
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Figure 30: Pathological changes dominate the morphological picture in patients with DMD gene 
mutations 
A-E: Representative illustration of the disease at different stages, inflammation was resolving until an age of 10 years 
and in older patients´ fibrotic tissue and fatty degeneration was dominant. Control groups showed less affection. F-J: 
Gömöri trichrome stain showed the same features and K-O: EvG staining illustrated fibrotic tissue. Scale bar = 100 µm 
 
4.5.3 The number of macrophages decreases with progression of the disease in DMD 
Cellular infiltration, especially by macrophages, was seen in the first decade of life in DMD patients (Figure 
31 A, B, F, G), while these cells were only scant in the fibrotic, fatty muscle tissue of older patients (Figure 
31 C, H). In BMD patients and in fC, infiltrates can also occur and if infiltrates were present, macrophages 
RESULTS 
- 50 - 
were the prevalent cell population (Figure 31 D, E, I, J). However, except from macrophages in infiltrates 
they were absent in the muscle tissue from BMD and fC. Expression levels of molecules associated with 
macrophage polarisation revealed that expression levels in BMD and fC were similar to those of NC 
(Figure 31 K). Nevertheless, in DMD patients the expression level of CD301 (CLEC10A) was significantly 
elevated when compared to NC and in cox2 (PTGS) a trend for up-regulation was identified (Figure 31 K). 
Dissected into the different sub-groups, DMD patients showed a stage-dependent expression of the 
molecules CD301, CD206 (MRC1) and cox2. While the latter was especially expressed in older patients, 
molecules of AAMs were more strongly expressed in younger patients (Figure 31 K). 
 
Figure 31: Macrophages are the predominant cell population in cellular infiltrates of DMD patients 
A-E: CD68+ cells in patients with DMD, fC and BMD. F-J: Staining with CD206. K: Expression levels of molecules 
associated with macrophages in comparison to NC (1 ≙ 10-fold increase). L: Molecules are further assessed in 
sub-groups of DMD patients. Statistical analysis in K, L were performed with Kruskal-Wallis one-way ANOVA with 
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Dunn´s multiple comparison test, p < 0.05 was considered significant (* ≙ p < 0.05, ** ≙ p < 0.01). Arrows indicate 
representative immunoreactive cells of the respective subtype. Scale bar = 100 µm 
To further analyze the involvement of macrophages in progression of the disease, the number of 
macrophages was counted in the whole biopsy and their distribution was analyzed. Between the 
patients high variations in the number of macrophage were seen, as shown by numbers of 
macrophages in single patients with DMD (Figure 32 C). In addition, the distribution of macrophages, 
e.g. confined to inflammatory infiltrates (high numbers/high power filed) or scattered within the muscle 
tissue (low numbers/high power field), varied strongly between patients, as well as inside a single 
patient (Figure 32 C). Nevertheless number of macrophages peaked in patients around the age of 4 
years, as seen in mean number of macrophages per high power field (Figure 32 A). Due to the high 
variation of macrophage distribution within the muscle biopsy of patients, as well as between the 
patients the correlation coefficient (R2) was only 0.1948. In Figure 32 B, the quantifications for patients 
with BMD, as well as fC are displayed together with DMD patients (fC R2: 0.7886; BMD: R2: 0.3573). 
In control groups macrophages were only scant and numbers were more or less unchanged at different 
ages. However, younger patients showed slightly higher number of macrophages than older patients 
(Figure 32 B).  
 
Figure 32: Numbers of macrophages changes with age of DMD patient, but not in BMD and fC 
A: The cell count in patients with DMD at various ages shows that amount of macrophages peaks at an age of 
around four years and numbers decrease over time. Macrophages are completely absent in older patients (~ 15 
years); B: CD68+ cells were additionally counted in BMD and fC, where the number of cells is low; C: The 
distribution of cells in individual DMD patients is displayed, the distribution varies strongly between patients, as 
well as within the biopsy of a single patient; D: Statistical evaluation of CD68+ macrophage distribution in DMD 
patients was done with Dunn´s multiple comparison test, p value < 0.05 was considered significant (* ≙ p < 0.05, 
** ≙ p < 0.01, *** ≙ p < 0.001). For cell count the average number of cells per 10 high power fields is shown. 
 
In addition to high numbers of macrophages, considerable amounts of lymphocytes were found in 
muscle tissue of young DMD patients (Figure 33 A, F, K), while there were only low numbers in tissue 
of older patients (Figure 33 C, F, M). B lymphocytes in general were not seen (Figure 33 K - M). In 
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control groups T lymphocytes were only scant (Figure 33 D, E and I, J) and B cells were also not 
detected (Figure 33 N, O). These pictures demonstrate that T cells seem to play only a minor role in 
progression of DMD pathology. 
 
Figure 33: Absolute numbers of lymphocytes are low in patients with DMD gene mutations 
A-E: Staining of CD4+ T cells, as well as F-J: CD8+ T cells and K-O: CD79a+ B lymphocytes in patients with DMD 
gene mutations. Arrows indicate representative immunoreactive cells of the respective subtype. Scale bar = 
100 µm 
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4.5.4 Development of fibrosis and muscle regeneration is strong in DMD, while 
control groups display only minor changes 
Development of fibrosis is considered one of the hallmarks in DMD and it has been shown that fibrosis 
directly correlates with early loss of ambulation 171. However, molecular analysis of expression levels of 
factors involved in the process has not been assessed in a systematic way yet. Automated whole slide 
image based quantification was used to analyse the development of fibrosis in patients over time (see 
methods p. - 24 -). Beside patients with DMD, BMD patients and fC were analysed and staining with 
collagen VI was used as basis for evaluation. Increasing amounts of fibrotic and fatty tissue were seen, as 
visualized by brown collagen staining and light, unstained fatty tissue (Figure 34 A-C). As especially 
observed in older patients the amount of fibrotic tissue was only one major part of muscle wasting, but the 
amount of fatty replacement was also considerably high (Figure 34 C). From the images, the ratio between 
muscle fibres and connective tissue was calculated. In DMD patients the ratio was changing over time, 
while in BMD and fC the ratio in all patients was similar (Figure 34 E, F, G). In DMD fibrotic tissue was 
increasing (Figure 34 A-C) and the variations in development of fibrosis within the group of DMD patients 
was high, depending on disease severity and age of patients. Additionally, the amount of fat was strongly 
increased in older patients, underlining the relevance of this process in muscle rebuilding (Figure 34 C). 
 
Figure 34: Increased fibrosis is seen in patients with DMD, but not in fC and BMD 
A-C: The amount of fibrosis and fatty tissue increased with age of DMD patients. D: Muscle tissue derived from NC 
was regularly stained with collagen VI, as well as E: fC. F: The same is true for BMD patients. G: Quantification of 
fibrosis on whole slide images is shown as ratio between muscle fibres and connective tissue. Scale bar = 100 µm 
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In addition to analyses of fibrosis via immunohistochemistry, molecules involved in fibrosis, like 
TGFB1, Prolyl 4-hydroxlase 1 (P4HA1), which is involved in collagen synthesis, as well as the 
chemokine CCL18, were evaluated. Most analyzed molecules were strongly and significantly 
increased when compared to NC (Figure 35 A), while in BMD patients and in fC displayed expression 
levels were comparable to those of NC (Figure 35 A). When DMD patients are dissected into 
subgroups depending on the phase of the disease, a stage-dependent expression pattern of some 
molecules was seen (Figure 35 B). The molecule CCL18, which is involved in early development of 
fibrosis, was significantly elevated in patients between 4-8 years (Figure 35 B, blue squares), while 
expression was only at the level of NC in older patients (Figure 35 B, red squares). Reduced 
expression levels fit to the observation, that fibrotic tissue was already developed in older patients. 
Interestingly SOCS1, a suppressor of fibrosis, P4HA1 and TGFB1 were not differentially expressed in 
the different stages of the disease (Figure 35 B). 
 
Figure 35: Molecules associated with fibrosis are elevated in patients with DMD, but not in control groups 
A: Molecules involved in fibrosis as compared to NC are displayed. B: When DMD patients are grouped according 
to phase of disease, a phase-dependent expression is seen. Statistical analysis in A, B were performed with 
Kruskal-Wallis one-way ANOVA with Dunn´s multiple comparison test was performed; p value < 0.05 was 
considered significant (** ≙ p < 0.01) 
 
4.5.5 Expression of cytokines/chemokines in DMD is dependent on the stage of disease 
In addition to the molecules involved in fibrosis, cytokine and chemokine profiles of pro- and anti-
inflammatory pathways were analyzed by qPCR to investigate potential activation in DMD. 
High variation within the expression levels of DMD patients was seen, while the control groups with 
BMD and fC again displayed very similar expression levels and they were not different from 
expression levels in NCs (Figure 36 A). These results fit the mostly weak symptoms found in BMD and 
fC. In DMD patients various molecules were strongly regulated, as IFNG. Additionally, IL6 and IL1B 
were significantly elevated in comparison to those in NC (Figure 36 A). 
As for molecules of fibrosis, also key factors of pro- and anti-inflammatory pathways were evaluated in 
a stage-dependent manner; however the molecules were not differently expressed in the different sub-
groups of DMD. Only IL6 and IL1B showed a trend towards higher expression in older patients (Figure 
36 B). In addition, interleukins IL12p40, IL17 and IL4 were exclusively expressed in DMD patients, 
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while no expression was detected in control groups (Figure 36 C), demonstrating an activation of both, 
pro- and anti-inflammatory pathways in DMD at a defined time frame during the disease. 
 
Figure 36: Cytokine and chemokine expression is stage-dependent in patients with DMD  
A: Cytokines in DMD patients were elevated when compared to those in NC. B: Expression profiles of molecules 
split into subgroups of DMD patients. C: Expression levels of interferons in all groups of patients. Statistical 
analysis was performed with Kruskal-Wallis one-way ANOVA with Dunn´s multiple comparison test. It was not 
possible to perform statistics for the expression of IL17, IL12, IL4, IL13 and IL5, because the respective cytokines 
were not expressed in normal controls; p value < 0.05 was considered significant (* ≙ p < 0.05, ** ≙ p < 0.01). 
 
4.5.6 Recapitulation 
Duchenne muscular dystrophy was characterized by increasing inflammation in young patients and by 
development of fibrosis in older patients. Patients with BMD or fC of the DMD gene mutation displayed 
less morphological alterations in general and can thus be used as control groups. Both groups 
harbored still some dystrophin expression, while inflammation, as well as development of fibrosis was 
weak. In contrast, DMD patients developed strong evidence of fibrosis, as it could be demonstrated by 
EvG and collagen VI staining. The ratio between muscle fibres and connective tissue/fat was 
decreasing in DMD patients, and on the molecular level, molecules involved in fibrosis, such as 
TGFB1 or the collagene synthetase (P4HA1) were significantly elevated in comparison to those in 
NCs. In addition, the amount of macrophages was quantified and the strongest activity and highest 
number of invading cells were seen in patients at an age of four years. After loss of ambulation 
(around the age of 10 years) the number of macrophages (as well as lymphocytes) decreased again.  
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4.6 Inflammatory infiltrates in IIM and MD 
The thorough evaluation of the inflammatory infiltrates in patients with NM, DM and DMD in the 
preceding chapters revealed overt differences in the composition of the inflammatory infiltrates in the 
entities IIM and MD. To give an overview about the composition, a semi-quantitative score of the 
involved cells is shown in Table 7. 
Although there was heterogeneity in the different entities, the overall composition of the cellular 
infiltrate was very characteristic. The data clearly illustrated that macrophages were the prevalent cell 
population in all examined diseases; however, the mere number of macrophages was varying 
between the entities. IMNM patients had the highest number of macrophages in biopsied skeletal 
muscles, demonstrating a strong activation of these multifunctional cells. As shown in chapter 4.3.2 
the macrophages were distributed across the whole muscle biopsy. In DMD the amount of 
macrophages can also vary strongly between individual patients. Here single macrophages were 
found scattered throughout the whole muscle biopsy, while a clear accumulation of cells in infiltrates 
was also seen. In addition to macrophages, T cells were also part of the infiltrate in all diseases, but 
their overall number is significantly lower in comparison to the number of macrophages. For example, 
IMNM patients had significant amounts of T cells, while they were less prevalent in nIMNM or DMD. 
Evaluation of B cells and plasma cells further revealed that these cells are only scant in all 
investigated entities, demonstrating a prevalence of T cell-mediated innate immunity. Involvement of 
the humoral immunity, in terms of pure numbers of B cells and plasma cells in the muscle tissue, is 
probably less relevant. 
 
Table 7: Composition of inflammatory infiltrates in IIMs and MD 
  
CD68+  
macrophages 
CD4+  
T cells 
CD8+  
T cells 
CD79a+  
B cells 
CD138+ 
plasma cells 
NM IMNM +++ ++ ++ - / + - 
 nIMNM + + - / + - - 
DM jDM ++ + + - / + - / + 
 aDM ++ + + - / + - / + 
DMD  + / ++ / +++ + + - / + - 
- = no cells detected; + = only single cells detected; ++ = clear accumulation of cells (~20 cells); +++ = 
significant numbers of cells (>30 cells) 
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5 DISCUSSION 
Human muscle diseases comprise a huge number of different entities, which may be inherited or 
acquired. Even if muscle diseases in general are relatively rare, all entities taken together affect 
thousands of people worldwide every year. The correct diagnosis is often difficult to obtain and in 
addition to the patients’ clinical history, laboratory results and results of electromyography, muscle 
biopsy and histological analysis are helpful to distinguish between the different diseases that may 
harbor considerable overlapping features. In the last years, the classification of muscle diseases is 
constantly growing larger and more complicated. As far as the immune inflammatory myopathies are 
concerned, recent work has clarified that the classical groups of IIMs, meaning dermatomyositis and 
polymyositis, are now much more precisely defined. On the one hand new groups and subgroups of 
certain entities are emerged and on the other hand the entity ‘PM’, which has been studied for 
decades and defined on certain criteria, has seriously been questioned as being a separate entity 75–
81,92,98. Therefore, I believe that at present very interesting new data on pathogenesis and aetiology of 
the IIMs will probably lead to a more exact classification of these diseases. Hence, before starting an 
investigation as done in the present thesis, the clinical and morphological diagnosis of each individual 
patient and assignment to a specific group and subgroup based on the present knowledge are of high 
importance. The first goal of this work was therefore, to identify characteristics in each entity and to 
group patients accordingly. The present data will contribute to the discussion about classification and 
pathomechanisms of the myopathies that were studied here. 
 
Muscle cells has been reported to react to injury or inflammation by secreting cytokines or chemokines 
(e.g. IL-6, IL-1, IFN-γ, CCL2) and attract immune cells to the site of injury 64,65. Furthermore, they 
initiate local differentiation of satellite cells or myoblasts and therefore actively support muscle 
regeneration 68. Macrophages, due to their multifunctional capacities, are also involved in a variety of 
reactions in the muscle. It has been shown, that during muscle injury macrophages are involved in 
clearing pathogens and perform a switch from pro-inflammatory to alternatively activated, wound 
healing-stimulating macrophage phenotypes 69,70. Although, the concept of classically and alternatively 
activation of macrophages is important, it has become increasingly clear that macrophages can adopt 
a multitude of intermediate phenotypes and probably polyfunctional ones as well. Additionally, fibrosis 
is initiated by TH17-like immune responses in interaction with regulatory macrophages 29. Disturbance 
of these interactions is also influencing regeneration 71, as well as repair mechanisms 68,73, and a 
multitude of other functions. Hence, macrophages are important players in autoimmune reactions in 
myopathies and might therefore be an essential target for specific therapies. 
Most of the examined inflammatory muscle diseases cannot be modeled in animal systems and even 
if there are existing animal models, they often only mimic single aspects of the disease. However, in 
1974 the first model of ‘allergic myositis’ (EAM) 209,210 was established in the rat by immunization with 
myosin, which resembles the concept of other autoimmune models, such as the experimental 
autoimmune encephalomyelitis (EAE). EAE has been adopted by other researchers and transferred to 
the mouse, mimicking aspects of ‘PM’ 147. One of the major drawbacks of this model is the fact that the 
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disease is not linked to a specific autoimmune antibody, which is known to be myositis-specific in 
humans 211. Another very interesting approach has also been published by the group of Ascherman, 
who investigated the innate immune response in a mouse model for anti-synthetase myositis by 
injecting Jo1 antibodies into mice 212. Even if this is a useful starting point to mimic a specific subgroup 
of myositis, to date, no convincing model is available. Therefore, using human skeletal muscle 
specimens has important advantages. The analyses open the possibility to directly correlate findings 
in the tissue to the current knowledge about the diseases themselves. In addition, as a future 
perspective, this approach might give reliable prognostic expectations with respect to a positive 
therapeutic response of patients and may help to develop personalized therapies. On the other hand, 
it is not possible to modulate molecular mechanisms only by analyzing human muscle samples; 
therefore the development and amelioration of murine models for myositis research are also of high 
importance. Although it is well known that certain pathomechanisms (especially the function of certain 
cytokines) in rats or mice may not have the same relevance as they do in humans.  
 
In the current thesis three different entities were analyzed, which all share common aspects of their 
immune response, but feature distinct immunological aspects as well. All entities have an inflammatory 
part in common, which is mainly regulated by influx of immune cells into the muscle tissue and 
manifestation of inflammatory cell infiltrates. However, the composition of these infiltrates is varying 
among the diseases and the involvement of e.g. T cells or macrophages is variable. In addition, the 
respective cytokine milieu in the muscle tissue is also different in the IIMs and in muscular dystrophies. 
Therefore the complex interaction of immunity and the skeletal muscle was investigated in the entities, 
as well as their distinct secondary effects, such as hypoxia, necrosis and fibrosis.  
 
5.1 Subgroups in NM can be distinguished by morphological features and 
differences in cytokine expression profiles 
Necrotizing myopathy is since recently considered a sub-entity of the group of IIMs and hence shares 
the ‘inflammatory part’ with the other groups like ‘PM’, DM and sIBM 76,77,82. Clear distinction of 
morphological alterations present in biopsies of these entities might sometimes be difficult and precise 
evaluation of characteristic features of each group is very important. Furthermore, in NM the general 
picture of the disease in patients with an immune-mediated background is basically similar to that in 
patients with a toxic-mediated aetiology, in terms of mere presence of necrotic muscle fibres. 
Nevertheless, reactions to therapy are quite different between these groups. Only patients with an 
immune-mediated background are treatable with immune-modulatory therapy, while patients with toxic 
aetiology would not benefit from these treatments in general 105,109. Therefore, I addressed the crucial 
question, if it is possible to distinguish the two groups (IMNM and nIMNM) by molecular and 
histological analysis. 
Interestingly, beside muscle fibre necrosis, both groups of NM showed a clear inflammatory infiltrate 
with macrophages invading muscle fibres. Macrophages were accompanied by CD4+ and CD8+ T cells 
in the infiltrate of IMNM patients, arguing for an interaction of macrophages and a T cell-mediated 
aetiology in most of the patients. However, some patients showed presence of B cells and plasma 
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cells, which in addition suggests a humoral immune component. This seemed not surprising, since 
many patients with autoimmune NM showed a strong positivity for myositis-specific autoantibodies 
(e.g. anti-SRP-autoantibodies). Current studies aim to clarify the humoral and also the T cellular part 
of the immune pathogenesis in in vivo and in vitro models (Benveniste and Boyer, personal 
communication). The presence of considerable amounts of immune cells found in this study are not in 
line with the results of many other researchers, who describe that NM is characterized by no or only a 
scant inflammatory infiltrate 91,92. Nevertheless, quantification of cells in the present study revealed not 
only considerable numbers of macrophages, but also of T cells in the biopsies of most IMNM patients. 
On the other hand, paucity of immune cells in the nIMNM biopsies was a regular finding in all 
specimens. Interestingly, the macrophages were only confined to necrotic muscle fibres and T cells 
were found in the proximity of necrotic fibres and fibres with myophagocytosis. Since quantification of 
these cells revealed significant differences between the groups, I believe that the mere presence of 
lymphocytes in the context of NM can be considered an element in favor of an immune-mediated 
aetiology. 
Since the common diagnostic strategy in myopathology involves the examination of presence or 
absence of certain patterns (such as inflammatory cells, expression of MHC molecules, complement 
deposition, fibrosis, vessel-associated pathology, mitochondrial function etc.), I included a thorough 
analysis of MHC class I molecules and complement deposition in NM patients. Under physiological 
conditions MHC class I molecules in the skeletal muscle are expressed on capillaries only; however, in 
IIMs up-regulation of MHC class I molecules on the sarcolemma proved involvement of the muscle 
cells in reactions of the immune system. In conjunction with several other molecules, e.g. ICOS, the so 
called immunological synapse between a CD8+ T cell and a MHC class I molecule can be established. 
The results of recent studies differ between amount and distribution of MHC class I expression 97,99,114, 
and for MAC deposition even the absence of expression is described as a typical feature of NM 
74,106,114. MHC class I expression in IIMs has already been studied decades ago by Emslie-Smith and 
colleagues 213, and interestingly also by McDouall 214 in DMD. Since then MHC up-regulation in IIMs 
can be considered a paradigm of an ongoing immune response. Therefore, it seemed surprising that 
in an autoimmune disease, as NM, MHC class I expression was reported to be absent 98. These 
authors also describe absence of inflammatory cells in their muscle specimens. In contrast to this, the 
data of the present study showed, that MHC class I expression in IMNM biopsies was robust and also 
found on non-necrotic muscle fibres. Although expression was heterogeneous in certain cases, it was 
regularly observed in distance of focal monocytic infiltrates. On the contrary, the expression in nIMNM 
patients was only low and confined to regions of myofibre necrosis or single necrotic and their 
adjacent fibres. The same picture was found for complement deposition. In IMNM patients the 
expression was widely distributed on the sarcolemma of muscle fibres and also detected on 
capillaries, while both features were completely absent in nIMNM cases. Remarkably, in IMNM 
especially patients with a paraneoplastic background and anti-SRP- autoantibodies or anti-synthetase-
syndrome showed strong expression of MHC class I and MAC deposition. These results underline the 
importance of studying certain immune aspects in a standardized manner to be able to assign patients 
to different subgroups. The clear documentation of the antibodies and methodological procedures 
used for histology in these cases are essential, since different antibodies might vary in their binding 
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strength leading to different results. For example in nearly all studies detection of complement 
deposition has been done with an antibody against C5b9 78,90,143. This is of cause reasonable, but 
since the C5b9 complex is the endpoint of the complement cascade, the different activation pathways 
are not covered. The investigation of factors involved in different pathways (e.g. C1q, C3 or C4 
antibodies) might therefore be also an interesting approach. 
In addition to the above mentioned features, presence of B cells has not been described in 
autoimmune NMs. However, some studies with a small number of patients or single patients used B 
cell depletion therapies with e.g. Rituximab 89,197. This approach was based on the concept that 
antibodies are involved in this disease entity and therefore B cells or B cell activation should 
theoretically play a role in the immune pathogenesis. However, a conclusive proof of this hypothesis 
has not been shown yet and the therapeutic success in these preliminary trials was heterogeneous. 
Therefore, I was interested in detection of B cells and plasma cells in the muscle biopsy specimens 
and also in the presence of associated B cell chemoattractants. In the present cohort of patients the 
analysis of B cells with immunohistology and molecular levels of the B cell chemoattractant CXCL13 
showed that B cells were only found in few patients with IMNM. Hence, the use of B cell blockers such 
as Rituximab or others 84,107,199 seems to be only reasonable in some patients, that can be identified by 
the features described here, but is probably of less importance in the majority of NM patients. 
Nevertheless, in refractory myopathies and in some NM patients with anti-synthetase syndrome or 
anti-SRP autoantibodies first encouraging results with Rituximab therapy were reported 201,215–217. 
Therefore, a careful analysis of B cell immunology before treating with further medications is essential 
to avoid unnecessary use of medications and reduce possible side-effects or interactions with other 
therapies. Interestingly, patients with certain autoantibodies showed stronger expression of the B cell 
chemoattractant CXCL13, as well as strongly up-regulated expression of MHC class I or MAC 
deposition. Therefore, the evaluation of autoantibodies in the patients´ serum is certainly also very 
relevant 95,100,101,218. However, it remains to be established, if patients endowed with specific 
autoantibodies relate to specific sub-groups defined by ENMC criteria and if they really have distinct 
immune pathomechanisms. Based on the findings of my work, ongoing investigations of IMNM 
patients are performed, with respect to presence of specific autoantibodies and special morphological 
or immunological features.  
 
Within this work I demonstrated that both sub-groups of NM can be clearly distinguished by their 
morphological characteristics, as well as by certain immune aspects, such as presence of 
autoantibodies, B cell invasion and also the underlying cytokine milieu. With knowledge of all of these 
factors, an adequate therapy for individual patients might be possible according to a defined immune 
profile, by e.g. TNF blocker, B cell blockers or other biologicals. 93  
 
5.2 Intrinsic hypoxia-associated pathways are more pronounced in jDM than in 
aDM patients 
The characteristic fact in patients with dermatomyositis is an appearance of the disease either in early 
childhood (Ø 7 years of age) or in adults at an average age of 60 years, while one does not meet this 
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feature in NM, sIBM or ‘PM’. It is well known that jDM and aDM share morphological features, as 
perifascicular atrophy of muscle fibres, complement deposition on capillaries and a characteristic 
inflammatory infiltrate, which have been reviewed and redefined in an international consensus 
conference recently 115. On the other hand, jDM patients show a very characteristic disease picture 
with some features that are not part of the disease in adults, including frequent dysphagia and 
calcifications of skeletal muscles. In addition there is a well-studied link of adult DM patients to cancer, 
which is not the case in jDM 95. 
Both diseases are considered inflammatory vasculopathies, although clear vasculitis with destruction 
of vessel walls (necrotizing vasculitis) is not apparent. Also it seems well established, that this 
vasculopathy leads to rarefication of capillaries, especially in perifascicular regions. One of the 
theories is that this is due to an endothelial damage and subsequent loss of capillaries of unknown 
cause. Ultrastructural analysis reveals tubuloreticular formations in these endothelia, which have been 
attributed to early stages of capillary loss. In a very recent work by Gitiaux and colleagues, it has 
elegantly been shown that vascular supply is profoundly impaired in DM patients 145. They could 
demonstrate that DM patients lose whole microvascular units instead of single capillaries, resulting in 
reduced blood supply. I hypothesized, that hypoxia-related phenomena may be involved in this 
vasculopathy, which may ultimately lead to perifascicular atrophy. Also I speculated that molecular 
pathways involved in inflammation may be linked to hypoxia. A candidate linking the above mentioned 
processes are macrophages 22,58. It was previously shown that macrophages in conjunction with T 
cells (mainly CD4+ T cells) are clustering around small arterioles in the perifascicular region and 
extending into the perimysium. Thus, I further speculated that these macrophages might interact with 
the ‘vessel compartment’ in a specific, yet unknown way. Therefore, pathways involved in 
inflammatory vasculopathy and hypoxia and their specific contribution in jDM and aDM were a central 
focus of this work.  
 
In this study I demonstrated that jDM patients are overall stronger affected and showed more 
symptoms than aDM patients. Therapeutic response to standard therapy (corticoid treatment and/or 
MTX treatment) was more successful in jDM than in aDM patients. In the studied cohort of aDM 
patients the therapeutic regime had often only little effect. Most patients described amelioration of 
symptoms, but complete and sustained remission was often not achieved. 
Classical morphological hallmarks of DM are perifascicular atrophy and inflammatory cells, which are 
mostly located perimysially, but may be also scattered throughout the muscle. 143,144 In this study jDM 
patients were more strongly affected by perifascicular atrophy than aDM patients, which was 
visualized by various histological stains. This phenomenon has not been pointed out before and 
although I found it quite striking, it has to be verified in a larger cohort of patients in the future. 
Therefore this observation was taken as a starting point to link atrophy to hypoxia. Indeed I found 
prominent staining of HIF-1α and VEGF in skeletal muscle fibres within the perifascicular region in 
jDM, which was not the case in aDM.  
Under normal conditions the whole body is continuously supplied with oxygen, but insufficient oxygen 
supply in single organs or tissues can be caused by e.g. pulmonary diseases, heart failure or different 
forms of vasculopathy 50–54. In aDM patients it was shown by Pestronk et .al. that capillary 
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damage/loss are concentrated in regions distant from the perimysium 143. However, by counting of 
single capillaries and muscle fibres I demonstrated that capillary loss is occurring in jDM patients in 
contrast to aDM where capillary loss was only seen in some patients. Correlation to the density of 
inflammatory infiltrates and degrees of perifascicular atrophy revealed that capillary loss is directly 
linked to these phenomena (Allenbach, Preuße, Stenzel, ongoing work). Inversely, muscle specimens 
displaying mild or no significant perifascicular atrophy and only scant inflammation showed no 
significant capillary reduction.  As suggested by Probst-Cousin et. al. up-regulation of factors involved 
in hypoxia might be an adaption to the deprivation of the blood supply 144. Various factors are involved 
in development of hypoxia or in regulating gene expression under hypoxic conditions (e.g. growth 
factors), one of the most important factors being HIF-1α. Up-regulation of this factor also seems to be 
important to mediate the deprivation of blood supply via angiogenesis 144. In addition VEGF, which is 
involved in angiogenesis and deposition of extracellular matrix 52,219,220, or the growth factor TGFβ, 
which is involved in tissue remodelling and fibrogenesis 221 are elevated in hypoxic tissue as seen in 
the current study. Inverse regulatory mechanism between these molecules are also suggested 222. In 
keeping with this, I showed an important involvement of hypoxia. Molecular analyses further confirmed 
these data, since molecules associated with hypoxia were strongly elevated on the mRNA level, 
especially in jDM patients. Here an elevated expression of HIF-1α, VEGFA and MIF was seen. Since 
these hypoxic changes are probably due to the reactions in the perimysium, as well as in adjacent 
atrophic muscle fibres, the isolation of these areas with laser microdissection was an elegant way to 
analyze the reactions without masking effects of neighboring ‘unaffected’ tissue. Although isolation of 
tissue with LCM is a useful technique to analyze specific regions/cells, it should be mentioned, that the 
laser isolation might affect the molecular profile of the isolated cells or tissue. Therefore, results from 
qPCR are quite interesting, but are not easy to compare to results from e.g. qPCR from whole-tissue 
isolates. For example, the amount of isolated RNA is lower and minor changes in cytokine profiles 
may not be correctly displayed. However, drastic changes in cytokine/chemokine expression were 
seen in LCM isolated tissue and especially prominent regulatory mechanisms can be revealed. By 
isolating the perifascicular area it is clear that effects of hypoxia and their regulation were confined to 
these atrophic areas in DM and non-atrophic, centro-fascicular tissue regions of the muscle fascicle 
are significantly less affected. Since morphological changes in DM were mostly confined to the 
perimysium, these results support the hypothesis that molecules involved in hypoxia indeed contribute 
to pathogenesis of jDM and in lesser extent to aDM. 
 
Beside perifascicular atrophy, a characteristic and well described inflammatory infiltrate was found in 
DM. However, in contrast to NM, where inflammatory infiltrates are scattered throughout the biopsy, in 
DM the inflammation was mostly confined to the perimysial area. In this region, inflammatory cells 
accumulated, with a clear predominance of macrophages, but also lymphocytes were seen. However, 
their number was significantly lower than the number of macrophages. Linking alternative activation of 
macrophages to vessel pathology, I was able to show a prominent presence of CD206+ macrophages 
in all of the examined specimens. This was mostly seen in the perifascicular region, while in the 
centro-fasciular region only scant CD206+ macrophages were identified. Although this was not studied 
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in further detail in the present work, it is planned to study a putative interaction of macrophages and 
endothelia in e.g. an in vitro setting. 
Comprising the findings, it became clear, that perifascicular atrophy and effects of the vasculopathy 
seemed to be the most important factors in progression of the disease. Since jDM patients are more 
strongly affected by vasculopathy and therefore by hypoxia and perifascicular atrophy, but react better 
to therapy, there might be a correlation between these phenomena. Is the higher regenerative 
capacity following atrophy the reason for a better responsiveness to therapy? Or do the immune cells 
react more strongly to therapy due to the young age of patients? These elements need to be further 
analyzed to ultimately find answers to these questions. 
 
5.3 Influx of macrophages and development of fibrosis are stage-dependent 
processes in DMD 
A number of inherited myopathies are known to also harbor significant inflammatory infiltrates, 
including the Duchenne muscular dystrophy, dysferlinopathies, and several others. The role of 
inflammation in these diseases is less well understood and also less studied than in IIMs, since it is 
generally believed that the inflammation is a secondary process. However, there are several lines of 
evidence, that this is not the whole truth, because already more than 20 years ago it was shown by 
McDouall and colleagues that MHC expression is strongly up-regulated, demonstrating an important 
influence of immune reactions in DMD patients 214. In addition, corticosteroids are considered the 
therapeutic gold standard in DMD, indicating that immunosuppression has a beneficial effect in this 
disease 223, while the exact mode of action is not clarified in all details. Conversely, the same 
therapeutic approach was inefficient in dysferlinopathies, where also considerable immune reactions 
take place 224. This indicates that the inflammatory reaction seems to be very specific in one entity and 
the putative therapeutic mechanism cannot be extrapolated to other diseases. 
Development of fibrosis is a hallmark of DMD and since fibrosis is directly correlated with an early loss 
of ambulation, as it has been shown in a study with a 10-year follow-up 171, understanding this process 
can represent a good starting point for specific therapeutic intervention. Current studies mostly focus 
on restoration of dystrophin expression by e.g. exon-skipping approaches. Pharmaceutical companies 
as e.g. GSK or Prosensa are developing components to skip various exons. As an example, Prosensa 
announced that agents for skipping of exon 51 are already in a clinical phase III trial (Prosensa 
webpage, 2014). These approaches seem very reasonable, since it has been shown in the mdx 
mouse model, that a restoration of about 20 % of dystrophin expression already improves pathology 
and performance in motor tests and the muscle is protected from exercise-induced damage 165. These 
findings are further supported by the morphological picture seen in patients with Becker muscular 
dystrophy or female carriers of the mutated DMD gene where a partial expression of dystrophin is 
found, which mainly prevents the DMD phenotype in these patients. 
However, also reduction of fibrosis or slowdown of its development may be equally important to 
increase the quality of life of the patients. Therefore, in this project I focused on the process of fibrosis 
and tissue remodeling, including fatty transformation, and the involvement of macrophages in 
progression of disease. As mentioned in the introduction, macrophages are strong players in 
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inflammatory processes and control various reactions in early inflammation and in fibrotic processes. 
In line with this, in the present work, I showed that over time both, inflammation and fibrotic tissue/fatty 
tissue was developing in DMD. However, after loss of ambulation the intensity of inflammatory 
processes decreased again. This was monitored by reduced numbers of inflammatory cells, as well as 
reduced expression of molecules driving inflammation. This led to the hypothesis that there must be a 
point in time (or a period) with high macrophage activity and additionally a phase of acute and active 
fibrogenesis. These phases might be simultaneous or subsequent events. Although, individually both 
phenomena have been studied before, a chronological link between them has not been formally 
established. 
Creating a new computer-based and specifically developed algorithm for tissue analysis I was able to 
quantify fibrotic tissue. In the analyzed cohort of patients at different ages, the amount of connective 
tissue increased with the age of the patients, while at late stage of disease (> 8 years) fatty 
transformation was an additional important issue. However, quantification of this fatty degeneration 
process proved to be complicated, since it is not easy to differentiate between fatty tissue (which is 
optically empty = white) and the translucent area beyond the tissue. Unfortunately, we did not find a 
valuable solution yet and therefore the precise quantification of fatty degeneration is part of ongoing 
investigations. Nevertheless, quantifications revealed that the ratio between muscle fibres and 
connective tissue was reduced in DMD in comparison to BMD and fC, demonstrating increased 
fibrosis in DMD patients. Older patients had a high ratio, since fibrotic and fatty tissue was the main 
components of the muscle, while muscle cells are only scant.  
Since fibrosis and loss of ambulation are correlated, the time-point for loss of ambulation might be 
delayed if the development of fibrosis is delayed 225. The process of fibrogenesis is probably tightly 
linked to the function and activation status of macrophages, since Desguerre et. al. link fibrosis to 
AAMs 171. In keeping with this statement, I showed that the highest numbers of AAMs are seen in 
patients around the age of four years and. Expression levels of e.g. CD206 (MRC1) and CD301 were 
also highest in the early and middle phase, supporting the findings by histology. In patients around 
four years, the fibrogenesis was starting, while the process was already advanced in patients older 
than eight years, which was paralleled by increased expression levels of fibrosis-associated 
molecules, such as the Prolyl hydroxylase or CCL18. In addition, at late time points only scant 
lymphocytes or macrophages were observed. These findings are supported by results from studies 
with the mdx mouse, where the switch of pro- to anti-inflammatory macrophages is associated with 
increased regeneration and tissue repair 188. Therefore, the balance between macrophage populations 
might influence the course of the disease. Despite the promising results in the mdx mouse model the 
correlation to the human situation is challenging, since the development of disease clearly differs 
between mice and humans. Not only is the progress of disease milder in mdx mice, the symptoms 
grow stable in older mice and neither the ‘clinical picture’ nor the morphological picture deteriorates 
further (reaching a plateau) 178. Therefore, I think that the role of macrophages and their impact on 
fibrogenesis in mice differs from that in the human situation and both conditions have to be studied 
comparatively. 
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It is well known, that progression of the disease in individual patients is happening at different speed, 
which is probably dependent on the genetic background and consecutive production of residual 
amounts of dystrophin protein. Therefore, not only the age of patients, but also the information that 
can be gained from muscle biopsy, e.g. active mediators, which mirror the stage of disease, is 
essential to understand heterogeneity of the disease. With this knowledge, a therapy targeting specific 
mechanisms at certain time points may be developed. Although corticosteroids are well established 
and the present use of corticosteroids is clearly beneficial, in daily practice it is often unclear when to 
start therapy and when to stop it, causing troublesome discussions in individual families. Based on the 
results of the present work, it seems appropriate to start therapeutic intervention at an early time point 
with anti-fibrotic therapy, since up-regulation of pro-fibrotic molecules was already a very early 
process. These data also point to the fact that fibrosis is not continuously developing during the 
disease; moreover it seems to be limited to the ambulatory phase. I clearly show that quantitative 
amounts of fibrotic tissue was not further increasing after the age of ten years, but nevertheless there 
is significant tissue remodeling after this time point with remarkable fatty tissue degeneration. 
Interaction of adipocytes with inflammation is a further challenge in DMD and has not been addressed 
at all. 
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6 CONCLUSION 
Comprehensive analyses of three human muscle diseases revealed that macrophages are 
underestimated cells contributing in different aspects of the immune reaction in myopathies. In all 
three entities macrophages are the predominant immune cell population and are involved in a variety 
of cellular processes, such as inflammation, hypoxia and fibrosis.  
Due to the fact, that all diseases have an inflammatory part in common, reduction of the inflammatory 
processes might be beneficial in all entities. In IMNM increased expression of pro- and anti-
inflammatory mediators was detected and infiltrates consist not only of macrophages but also of T 
cells, while toxic NM displayed a different morphology. Based on these results, the most interesting 
fact is that classification of patients into IMNM or nIMNM is possible by thorough morphological 
analysis, as well as by assessment of molecular mediators. In addition, IMNM patients often showed 
special features when specific autoantibodies were present. Future investigations should therefore 
focus on subgroups in NM with distinct autoantibodies, like anti-Jo1- or anti-SRP-autoantibodies. Here 
a correlation of antibody appearance and special clinical phenomena is an important research 
objective. Ongoing work in our group therefore focuses on analysis of Jo1+ patients and it was shown 
that important morphological changes occurred inside the nucleus. We were able to illustrate that 
intracellular trafficking of actin is impaired. Additional investigations are needed to explain this specific 
pathophysiology. 
To clarify the pathogenesis in patients with DM, beside evaluation of cellular infiltrates, the extent of 
hypoxia was an additional important feature. I demonstrated that jDM patients were more strongly 
affected by the vasculopathy. In addition, capillary loss was especially occurring in jDM or more 
strongly affected aDM patients. Localization of hypoxic molecules in the perimysium was 
demonstrated. Since AAMs were predominant in these areas, future research of our group will focus 
on the interactions between macrophages and vessels in an in vitro model. 
The present data reveal that in DMD the infiltration of immune cells was a time-dependent process 
and was closely associated with fibrogenesis. In this case AAMs were the predominant cell population 
in the middle phase of the disease, and their activity was a crucial factor in disease development. 
Therefore the slow-down of fibrogenesis, leading to prolongation of the mobile phase, may be the key 
for increasing the quality of life of the patients. Continuing studies should therefore transfer these 
findings to a mouse model and correlate the disease stages of humans to the corresponding stages in 
mice. Here the mdx model or other mouse models, e.g. mdx/utrn-/+, which more closely reflect the 
human situation 183, are notably. The use of mouse models might be helpful, since e.g. the process of 
fibrogenesis can be influenced through application of therapeutics, such as anti-fibrotic medication or 
by immune-modulation. Also crossing these mice with mice harboring a genetic modification of 
relevant molecules can be helpful to further dissect mechanisms that are important during 
development of the disease. 
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SUPPLEMENTAL DATA 
Supplemental Table 1: Clinical findings of patients with necrotizing myopathy 
Patients grouped as immune-mediated (16 patients), non-immune-mediated (8 patients) 
 patientnumber age gender 
CK 
(x-fold) 
auto-Ab 
(MAA/MSA) 
systemic disease  
(autoimmune or paraneoplastic) treatment/ clinical follow-up 
im
m
un
e-
m
ed
ia
te
d 
N
M
 
1 57 f 14x 
ANA 1:1280, 
PL-7, PL-12, 
Ku, Ro52 
Sjögren’s syndrome, antisynthetase 
syndrome 
multiple cycles of treatment with steroids, 2 cycles of Rituximab, 
multiple cycles of IVIG; MTX 
still considerable dyspnoea, improved muscle strength  
2 74 m 5x - colon-cancer   treatment of colon carcinoma with resection and adjuvant chemotherapy 
3 80 f 10x n.d. primary biliary cirrhosis (PBC) treatment with steroids 
4 36 f 46x Ro-52  Raynaud’s syndrome 
treatment with multiple regimens of steroids 
multiple cycles of IVIG 
subjective improvement of Raynaud’s syndrome and muscle 
weakness 
5 66 m 41x SRP renal cell carcinoma treatment with steroids, tumor resection (nephrectomy) subjective improvement of muscle weakness 
6 57 m n.d. ASMA squamous cell carcinoma treatment of carcinoma with chemotherapy treatment with steroids without improvement 
7 19 f 78x SRP infection with Chlamydia, 6 months prior to muscle symptoms 
Chlamydia treatment with Doxycyclin 
1st line steroids: partial recovery; 2nd line IVIG & steroids: 
recovery; maintenance treatment: Azathioprine & low dose 
steroids 
complete cessation of any treatment due to pregnancy 
8 55 m 47x n.d. Non-Hodgkin lymphoma lymphoma treatment with chemo- and radiotherapy  
9 63 f n.d. SRP symptoms started after viral infection a few months earlier treatment with steroids, MTX 
10 37 f n.d. ANA 1:2560,  Ro-52  
treatment with steroids 
mild improvement 
11 64 f 35x Jo-1 
rheumatoid arthritis, interstitial lung 
disease 
antisynthetase syndrome 
1st line steroids: recovery; 2nd line IVIG & steroids: recovery 
maintenance treatment: IVIG & low dose steroids 
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12 79 m 2,4x AChR myasthenia gravis, obstructive airway disease 
treatment with steroids and Kalymin: without improvement 
cessation of Kalymin and high dose steroids followed by 
reduction of steroids and maintenance therapy with AZT 
13 68 f 71x Jo1 Anti-synthetase syndrome treatment with steroids 
14 37 f 51x Jo1 Anti-synthetase syndrome no information about treatment and follow-up 
15 71 f 45x  adenocarcinoma of the lung tumor resection, treatment with steroids: mild improvement maintenance therapy of 30mg prednisolone required 
16 47 m 5x  chronic lymphatic leukemia stage A(I); polyneuropathy 
CLL therapy: steroids, Rituximab, fludarabin, cyclophosphamide 
3 cycles 
followed by high dose IVIGs and cyclophosphamide 
 patient number age gender CK 
auto-Ab 
(MAA/MSA) toxic agent / clinical aspect treatment / clinical follow-up 
no
n-
im
m
un
e-
 
m
ed
ia
te
d 
N
M
 
17 52 f 33x n.d. malarone  
18 62 m 90x - simvastatin, Voriconazole stop of medication with voriconazole and statins 
19 55 f 15x - simvastatin stop of statins, with subjective partial improvement; addition of steroids 
20 76 m 900x n.d. acute renal failure, dialysis, diabetes mellitus dialysis, no further information available 
21 53 f 50x - Quetiapine* methylprednisolone, no further information about course of disease available 
22 75 f 300x - simvastatin stop of statins, forced diuresis, CK drops to normal no further information about clinical long term course available 
23 33 m 36x n.d. alcohol excess discharge from hospital with benzodiazepine and Paracetamol 
24 70 f 93x n.d. simvastatin no further information about clinical long term course available 
 
nd.: no data; mo: months; f: female; m: male; Ab: antibody; AChR: acetylcholine receptor; ASMA: alpha smooth muscle actin; IVIG: Immunglobulins; MTX: methotrexat 
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Supplemental Table 2: Clinical findings of patients with dermatomyositis 
Patients grouped for juvenile DM (15 patients) and adult DM (11 patients) 
 patient number age gender tubuli 
CK 
(x-fold) symptoms therapy success of therapy 
ju
ve
ni
le
 d
er
m
at
om
yo
si
tis
 
25 15 f + 50x mw, s, d, si 
MTX, Cyclosporin A, high dose corticoisteroids (1mg/kg) 
later additionally Hydroxychloroquin 
complete remission, no sign of 
calcification 
26 7 m +  mp, si, d, mw 
Prednisolon therapy (40mg/d 8we) after relapse MTX 
Methylprednisolon (3d/every 2we), IVIG 30g, 3/d 
Methylprednisolon 
remission, relapse after dose reduction, 
27 2 m + 3,1x si, s Prednisolon, MTX, folic acid remission, relapse after dose reduction 
28 5 f n.m. 4,5x si, mw, mp 
6-12 we Corticoids: Decortin and Prednisolon 20mg/d 
due to side effects, change in therapy: Prednisolon, 
Azathioprin 
remission, side effects, change of therapy, 
clear remission 
29 4 f n.m. 2x mw, mp Methylprednisolon-pulse, MTX remission, slight relapse, then complete remission 
30 8J 10M m + normal mw, si, s 
high dose Methylprednisolon IV, Cyclosporin A, 
Prednisolon 
due to side effects, change of therapy: Urbason, MTX 
remission, side effects, change of therapy, 
complete remission 
31 13J 8M m +   Urbason, MTX clear improvement 
32 11J 3M f n.m. 20,2x mw, mp Urbason, MTX clear improvement 
33 3J 11M f + 4,6x mw, mp, si, d Methylprednisolon therapy slight improvement 
34 9J 1M f + 2,9x si, mw, mp Urbason pulse 650mg over 3d complete remission 
35 4 m n.m.  mw, mp, fever, s, si 
MTX, Prednison 
4we cortison  therapy, Methotrexat, Decortin 
improvement 
relapse and change in therapy 
36 ca. 1J f n.m.   Urbason, decortin therapy 1mg/d complette remission Urbason stopped, without problems 
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37 10 m + normal si, mw, mp 
Prednisolon 20mg - 0 - 10mg, MTX 15mg/1/we; Urbason 
therapy 3x500mg on 3 consecutive days and 30mg IgG 
IV 
change in therapy due to muscle pain: MTX 15mg 
time of discharge from hospital Prednisolon 12,5mg/d, 
MTX 15mg 1x/we 
clear remission 
slight relapse with pain 
change in therapy: remission 
38 8 m n.m.  mw, si, a Urbason pulse therapy 20mg/kg 3d, MTX 15mg/we 
Remission 
Relapse after infection 
Remission 
39 14 m n.m. 15x mw, mp, si Methylprednisolon therapy 1g/d on 3 consecutive days, MTX 25mg 1x/we, Vigantolette 500 I.E/d First no effect, than remission, CK normal 
 patient number age gender tubuli 
CK 
(x-fold) symptoms therapy success of therapy 
ad
ul
te
 d
er
m
at
om
yo
si
tis
 
40 44 f +  mw, s, a 
Azathioprin 125mg/d, Prednisolon 12,5g/d, MTX 1/we 
Quensyl/Urbasol 
Prednisolone reduced to 7,5mg/d 
weakness decreased, skin unchanged 
change of therapy no remission, strong 
side effects 
Prednisolon reduced 
41 71 m + 22,5x si, mp, d Methylprednisolon 500mg IV dosis reducsd 
remission, CK normal 
relapse 
42 56 f + 20x mw Prednisolon CK decreased 
43 49 f +  mw Corticosteroids 20mg  
44 58 m  8,4x s Prednisolon iV (250mg, 100mg) remission 
45 86 f + 10,3x mw Corticoid therapy no effect 
46 78 f   t Prednisolon 20mg  
47 55 m  25,7x mw, mp   
48 52 f  normal mp MTX Prednisolon IV (250mg, 100mg) no effect 
49 83 f + 2.5x mw, t, d, si Prednisolon 2mg/kg reduced to 1mg/kg, Azathioprin remission, CK normal 
50 44 f + normal mw, mp, mya, a MTX 7.5mg/we  
Symptoms: muscle weakness = mw, muscle pain = mp, arthralgia = a, skin involvement = si, dysphagia = d, swelling = s, tetraparesis = t; mya = myalgia; n.m. = no material for EM studies; nd.: no 
data; mo: months; f: female; m: male; IVIG: Immunglobulins; MTX: methotrexat 
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Supplemental Table 3: Clinical findings of patients with Duchenne muscular dystrophy and control groups 
Displayed are all available information about symptoms, further diseases and treatment of the DMD patients (25 patients) and control groups (female carrier of the DMD gene: 5 
patients, and Becker muscular dystrophy: 6 patients) 
 patient number age gene mutation symptoms medication/therapy 
D
uc
he
nn
e 
m
us
cu
la
r d
ys
tr
op
hy
 
51 3,11 Dup Ex 56-63 cardiomyopathy, respiratory insufficiency, mild mental retardation, wheelchair dependent 
Enalapril 2x/d 3mg; Carvedilol 2x/d 6,25mg  
physiotherapy, swimming each 1x/we 
52 12,1 no information available cardiomyopathy, wheelchair dependent, respiratory support at night, nutrition via PEG-tube Metoprolol, Hydrochlorothiazid   
53 10,1 no information available   
54 14,00 no information available Scoliosis, cardiomyopathy, respiratory support, wheelchair dependent 
Propranolol (Obsidian) 1x6,25mg, Enalapril 2x5mg, 
Hydrochlorotiazid 2x12,5mg, Movicol 1TL/d 
55 7,90 no information available   
56 1,30 PM Base Exon 40 (c.5620G-->T) 
migraine, decreasing muscle strength, initial wheelchair 
dependency, positive Gowers’-sign 
Calcort 30mg/d, physiotherapy, logopaedics, 
psychotherapy, swimming each 1x/we 
57 3,70 Point mutation Ex 17 biopsy at ~4 years of age: CK 190-fold at age 11: loss of ambulation, multiple contractures At age 11: Prednisolon, PTC study 
58 4,11 no information available 
to small, to light, problems climbing stairs, positiv Gowers’-
sign, muscle weakness proximal, gnome calves, mental 
retardation 
 
59 3,80 no Del/Dup found CK 197-fold, proximal weakness, walking only short distances, learning disability, aggression no medication 
60 1,80 Del Ex 50 and 54-60 
motor retardation, mother genetic proven carrier of DMD 
gene, mental retardation, speech development only 
rudimentary, proximal weakness, hypertrophic calves 
Deflazacort 
61 11,50 no del/dup found proximal weakness, wheelchair dependent since age 9, CK up to 100-fold  
62 0,90 Del Ex 48-50 hepatomegaly, CK 60-fold, proximal weakness  
63 3,11 Del 3-12 in frame proximal weakness, CK 125-fold, positiv Gowers’-sign L-Carnitin, Vit B Complex, Coenzym Q10 
64 6,50 Del Ex 48 
biopsy at six years of age: muscle weakness, no cramps, no 
pain, no familial genetic background, hypertrophic calves, 
CK > 3,5-fold 
currently 14 years: adipose, loss of ambulation  
Prednisolon 
65 5,80 Dupl Ex 2 positive Gowers’-sign, limited strength/motor capacities since age 3, CK > 100-fold  
66 4,30 Del Ex 10-13 in frame uncle died at 25 years of age, also genetically proven DMD, loss of ambulation at age 8, early development of scoliosis,  
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prominent contractures 
67 7,40 Del Ex 45-45 in frame  CK > 20-fold  
68 5,11 no information available   
69 5 Del Ex 51 
combined developmental disorder, starting heart 
insufficiency, wheelchair dependent, learning disorder, CK 
36-fold, loss of ambulation at age 7 
beta-blocking agents 2x0,5/d, Movicol 1 Btl/d 
cortison no effect 
70 3 no information available   
71 1 Del Ex 49-52 CK 80-fold  
72 2 Del Ex 19 CK 150-fold, mental retardation, proximal weakness, hypertrophic calves, positive Gowers’-sign  
73 5 c.4438_4439insCA;p. (Glu1480Alafs*3) proximal weakness, speech development delayed Deflazacort 
74 22 no information available   
75 6 no mutation found proximal weakness, multiple contractures, hypertrophic calves, positive Gowers’ sign  
 patient number age gene mutation symptoms medication/therapy 
fe
m
al
e 
D
M
D
 
ca
rr
ie
r 
76 6 no information available     
77 12 no information available     
78 32 c.4438_4439insCA;p. (Glu1480Alafs*3) cardiomyopathy ACE inhibitors, beta-blocking agents 
79 50 no analyzes     
80 56 no information available     
 patient number age gene mutation symptoms medication/therapy 
B
ec
ke
r m
us
cu
la
r 
dy
st
ro
ph
y 
81 12,90 Del Ex 45-47 in frame 
proximal weakness, CK 30-fold, foot drop since age 6, 
reduced muscle strength, hypertrophic calves, positive 
Gowers’ sign 
 
82 23,00 no information available increasing walking problems, reduction of breathing capacity, hip problems  
83 2,90  no information available cardiomyopathy, initial wheelchair dependency, weak scoliosis, positive Gowers’-sign, weakness of pelvic girdle Calcort 6, 5/d 
84 24  no information available    
85 43  c.650-3C>A hemizygous no information available  
86 34 no information available no information available  
Del = deletion, Dup = duplication 
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Supplemental Table 4: Clinical information for healthy normal controls 
 
patient 
number age gender 
time since onset of 
symptoms (mo) CK 
auto-Ab 
(MAA/MSA) Symptoms/ treatment 
no
rm
al
 c
on
tr
ol
s 
88 47 m -- normal - diffuse myalgia & arthralgia, no treatment 
89 41 f -- normal - myalgia, no treatment 
90 2 m -- normal - *, no treatment 
91 57 f -- normal - myalgia, no treatment 
92 55 m -- normal - myalgia, no treatment 
93 13 f -- normal - Epilepsy, medication Felbamat, Primidon 
94 1,75 m -- normal - dystonic movement disorder  
95 7,5 f -- normal - diffuse myalgia, no treatment 
96 26 m -- normal - Recurring subjective weakness, no treatment 
 
* Mother with a history of malignant hyperthermia; therefore, due to an upcoming operation of the heart in her child, the risk for malignant hyperthermia in the child was 
excluded, among other means by doing a muscle biopsy which was entirely normal
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… all denen, die unsere Projekte und meine Stelle finanziell unterstützt haben. Im Einzelnen: der 
FAZIT-Stiftung, der Sonnenfeld-Stiftung, der action Benni & Co. und der DGM. 
 
… meinen Kollegen, für die wunderbare Zusammenarbeit und die vielen Anregungen für meine 
wissenschaftliche Arbeit. Nicht nur den Arbeitsalltag, sondern auch unsere vielen privaten 
Unternehmungen werden mir in guter Erinnerung bleiben!   
 
   
  
EIGENSTÄNDIGKEITSERKLÄRUNG 
Hiermit erkläre ich, Corinna Preuße, dass die vorliegende Dissertation zum Thema: ‘Common and 
distinct immunological aspects in acquired inflammatory myopathies and inherited muscular dystrophy’ 
selbstständig verfasst wurde und keine anderen als die angegebenen Quellen und Hilfsmittel 
verwendet wurden. 
 
 
Berlin, den 16. Juni 2014 
Corinna Preuße 
 
